SYSTEM FOR THE ASSEMBLY AND MODIFICATION OF NON-RIBOSOMAL PEPTIDE SYNTHASES

Abstract

The present invention pertains to a system for the assembly and modification of non-ribosomal peptide synthases (NRPS). The system uses novel well defined building blocks (units) comprising condensation subdomains. This strategy allows for the efficient combination of assembly units referred to as eXchange Units (XU2.0) independent on their natural occurring specificity for the subsequent NRPS adenylation domain. The system of the invention allows for the easy assembly of NRPS having any amino acid sequence of choice, without any restrictions due to natural occurring NRPS units. The system also allows the exchange of natural NRPS building blocks with the inventive XU2.0 leading to the production of modified peptides. The invention provides the system, their individual exchange units, nucleic acids encoding these units, as well as methods and uses thereof.

Description

FIELD OF THE INVENTION

[0001] The present invention pertains to a system for the assembly and modification of non-ribosomal peptide synthases (NRPS). The system uses novel well defined building blocks (units) comprising condensation subdomains. This strategy allows for the efficient combination of assembly units referred to as eXchange Units (XU.sub.2.0) independent on their natural occurring specificity for the subsequent NRPS adenylation domain. The system of the invention allows for the easy assembly of NRPS having any amino acid sequence of choice, without any restrictions due to natural occurring NRPS units. The system also allows the exchange of natural NRPS building blocks with the inventive XU.sub.2.0 leading to the production of modified peptides. The invention provides the system, their individual exchange units, nucleic acids encoding these units, as well as methods and uses thereof.

DESCRIPTION

[0002] Non-ribosomal peptide synthetases (NRPSs) and polyketide synthases (PKSs) are multifunctional enzyme complexes harboring a modular architecture (Marahiel 1997). Numerous natural products synthesized by these enzyme classes are of pharmaceutical and/or biotechnological interest because of its medicinally relevant properties including antimicrobial (e.g. teixobactin), antitumor (e.g. bleomycin), antifungal (fengycin) and immunosuppressant (cyclosporin) activity (Ling et al. 2015, Ishizuka et al. 1967, Loeffler et al. 1986, Emmel et al. 1989). Although the peptidic compounds produced by NRPSs exhibit a broad range of bioactivity and a great structural variety (e.g. non-proteinogenic amino acids, N-methylation, epimerization, heterocycles), a common mode of synthesis is shared, the so called "multiple-carrier thiotemplate mechanism".

[0003] The structure of NRPSs is obligate modular. A module is defined as the catalytic unit that incorporates one specific building block (e.g. amino acid) into the growing peptide chain (Marahiel 1997). NRPS modules can be subdivided into domains and each domain is responsible for a certain reaction step within peptide assembly. For example, a canonical elongation module is composed of three domains, denoted as core domains:

[0004] adenylation (A) domain which selectively determines and activates substrates (usually amino-acids) as an amino acyl adenylate.

[0005] A peptidyl carrier protein (PCP), also called thiolation domain (T) binds the cofactor 4-phosphopantethein, to which the activated amino acid (AA) is covalently bound by thioester formation.

[0006] A condensation (C) domain catalyzes peptide bond formation between the downstream and upstream located aminoacyl or peptidyl residues.

[0007] The first (N-terminal) module (start module) of a NRPS module often possesses no C domain and the last (C-terminal) module (termination module) usually contains a thioesterase (TE) domain (Marahiel et al. 1997). The TE domain usually is responsible for the release of linear (transfer to a water molecule), cyclic or branched cyclic peptides (amide or ester linkage).

[0008] The following domains may be included within a NRPS: C (condensation), Cy (heterocyclization), A (adenylation), T (thiolation) or PCP (peptidyl carrier protein), TE (thioesterase), E (epimerization), condensation/epimerization (C/E), MT (methyltransferase), Ox (oxidase), and Re (reductase) domains. NRPSs generally have the following structure: A-T-(C-A-T)n-C-A-T-TE where A-T is the initiation module, C-A-T are the elongation modules, and C-A-T-TE is the termination module. Within the individual modules, the following variations may, for example, occur: C is replaced by Cy or C/E, and E, MT, Ox, or Re are inserted; TE is replaced by C or Re. A complete assembly line may have an initiation module, a termination module, and somewhere between zero and n-2 elongation modules, where n is the number of monomers in the polymeric product. Exceptions to this rule may exist; e.g., the enterobactin synthetase, in which the TE domain acts as an oligomerase, so although it only has two modules, it hooks three of these dimeric products together to form a hexameric peptide product.

[0009] NRPSs are generally modular, and the series of catalytic steps moves from the amino to carboxy terminus of each polypeptide that makes up the NRPS. For example, the NRPS that produces tyrocidine is made of three genes producing three polypeptides. TycA contains the initiation module; TycB contains three elongation modules, and TycC contains six additional elongation modules plus a termination module.

[0010] The following domains may be included within a PKS: KS (ketosynthase), AT (acyltransferase), T (thiolation), KR (ketoreductase), DH (dehydratase), ER (enoylreductase), TE (thioesterase). PKSs generally have the following structure: AT-T-(KS-AT-T)n-TE. AT-T is the initiation module, KS-AT-T are the elongation modules, and TE is the termination module. The structure of a PKS is very similar to NRPS structure. There are many examples (e.g., yersiniabactin, epothilone, Neomycin) of hybrid PKS-NRPS systems in which both types of assembly line are pieced together to form a coherent unit. Within each PKS module, one either finds a KR, a KR and DH, a KR and DH and ER, or no additional domains. These extra domains within a module determine the chemical functionality at the beta carbon (e.g., carbonyl, hydroxyl, olefin, or saturated carbon).

[0011] The power of NRPs and PKs as potential drugs lies in their diverse and complicated chemical structures. Generally, it is the intricacy of these natural products that makes them (or variants thereof) difficult to access synthetically. Several examples exist where laborious synthetic routes have been developed, rarely successfully, for NRPs or PKs. Additionally, various moieties on such molecules are inaccessible to modification by organic synthesis, or can only be produced at low yields using such techniques. This difficultly in synthesis and modification of the NRP and PK natural products underscores the need for alternative strategies to enhance synthesis and create variants of these molecules.

[0012] Despite the apparent modular structure of the NRPSs, it has, prior to the inventor's previous invention (EP15002340) and the present invention, in practice been difficult to swap domains so that the resulting NRPS is active. Substitution of one or more domain or modules for another generally results in low yields (e.g., >10-fold reductions) and in the production of undesirable biosynthetic side products. These changes may be a result of disruptions of protein-protein interactions and due to the substrate specificities of C and TE domains, respectively. Thus, there is a need for new methods to produce novel NRPs and PKs and a need for methods that increase the yields of such NRPs and PKs.

[0013] For further general information on NRPSs and PKSs see Cane et al. (1998), Marahiel (1997), Sieber and Marahiel (2005), Smith and Tsai (2007) and Sussmuth and Mainz (2017).

[0014] After activation and covalent binding of the first AA by the A-T didomain initiation module, peptide elongation proceeds by subsequent condensation with building blocks covalently tethered to T domains of the downstream (C terminal) elongation modules (C-A-T)n (Sieber and Marahiel 2005 or Sussmuth and Mainz 2017). All elongation reactions (peptide and amide bond formation) are mediated by ca 450 AA long C domains, located in between the upstream T and downstream A domain and are strictly unidirectional leading to a downstream-directed synthesis of the NRPS product (Samel et al. 2007). C domains catalyze the nucleophilic attack of the downstream T domain bound acceptor AA with its free .alpha.-amino group on the activated thioester of the upstream T domain bound donor AA or peptide.

[0015] Biochemical characterizations of C domains revealed insights into their catalytic role and substrate specificities. Via deletion experiments Stachelhaus and colleagues (1998) brought to light that C domains are indispensable for peptide bond formation. Furthermore, sequence alignments of several C domains revealed a highly conserved HHXXXDG sequence motif (the so called "His motif") that is also present in acyltransferases (e.g. chloramphenicol acetyltransferase), NRPS E, and Cy domains (De Crecy-Lagard et al., 1995). Mutations of the second His residue in the conserved motif abolished activity in condensation assays (Sieber and Marahiel 2005).

[0016] Structures which include NRPS C domains have been determined by X-ray crystallography: a stand-alone C domain (Keating et al., 2002), a C-T didomain (Samel et al., 2007) and a C-A-T-TE termination module (Tanovic et al., 2008). C domains have a pseudo-dimer configuration, with both N- and C-terminal subdomains having cores with folds in the CoA dependent acyltransferase superfamily (Bloudoff et al. 2013). The active site is at the bottom of a "canyon" formed by the two subdomains, and is covered by a "latch" that crosses over from C to N subdomain. The catalytic center, including the HHXXXDG (where X denotes any residue) motif, has two binding sites: one for the electrophilic donor substrate (the acyl group of the growing chain) and one for the nucleophilic acceptor substrate (the activated amino acid) (Rausch et al., 2007).

[0017] Although, little is known about the reaction C domains catalyze, biochemical characterization of different C domains from the tyrocidine synthetases (Belshaw et al. 1999; Clugston et al. 2003; Samel et al. 2007) revealed insights into their substrate specificities. All C domain characterizations were performed in vitro and used the same method to investigate the substrate acceptance of internal C domains. The upstream and/or downstream T domains were chemo-enzymatically primed (transfer of synthetic peptidyl-Ppan arms) with acceptor substrates by the use of the permissive PPTase Sfp (Belshaw et al. 1999; Samel et al. 2007). In summary, with this method it was shown that the acceptor site of the C domain exhibits a strong stereo and significant side chain selectivity (Rausch et al. 2007). The selectivity towards a specific side chain seems to be less pronounced at the donor site which exhibits strong stereo-selectivity. C domains succeeding E domains show specificity towards the configuration of the C terminal residue bound at the donor site because the preceding E domain doesn't specifically catalyze the epimerization from L to D, yet provides a mixture of configurations. C domains immediately downstream of E domains were shown to be D-specific for the upstream donor and L-specific for the downstream acceptor, thus catalyzing the condensation reaction between a D- and an L-residue (Clugston et al., 2003).

[0018] C domains can be subdivided into functional and phylogenetic subtypes (Rausch et al. 2007). There are "standard" C domains within elongation modules like .sup.LC.sub.L domains, which catalyze peptide bond formation between two L-AA, and .sup.DC.sub.L domains connecting a L-amino acid to a growing peptide ending with a D-amino acid (Rausch et al., 2007). Starter C domains acylating the first amino acid with a carboxylic acid (often a .beta.-hydroxyl fatty acid) and heterocyclization (CY) domains which catalyze both peptide bond formation and subsequent cyclization of cysteine, serine or threonine residues (Rausch et al. 2007). The homologous Epimerization (E) domain flips the chirality of the last amino acid in the growing peptide and Dual C/E domains catalyze both condensation and epimerization.

[0019] The most common way of multienzyme reactivation is via TE domains, which belong to the .alpha./.beta.-hydrolase superfamily (lipases, proteases and esterases) (Du and Lu 2009). These enzymes are ca. 280 amino acid long and are fused to most C-terminal T domain of the termination module (Sieber and Marahiel 2005; Kohli et al. 2001). In the last step of peptide assembly an active site serine of the TE domain carries out a nucleophilic attack on the T domain-peptidyl thioester to form a peptide-O-TE intermediate (Kohli et al. 2001). Deacylation of the intermediate involves either hydrolysis (attack of an exogenous nucleophile) to release a linear peptide or, in the case of cyclic products, reaction of an intramolecular nucleophile (N-, O-, or C-nucleophile). Hydrolytic release is observed for peptides such as vancomycin, whose peptide backbone is constrained by further post-synthetic oxidative cross-linking reactions. Cyclizing TE domains provide a source of diversity and complexity as a variety of groups can be the nucleophile in the cyclization reaction: the N-terminal amino group (head-to-tail cyclization; e.g. tyrocidine A and gramicidin S), a side chain nucleophile (branched cyclic molecule; e.g. bacitracin A and daptomycin), and the .beta.-hydroxyl group of a .beta.-hydroxy fatty acid (e.g. surfactin) (Kohli et al., 2001).

[0020] Bruner et al. (2002) solved the first TE crystal structure of the surfactin biosynthesis cluster (SrfTE). In general NRPS TE domains are monomers and consist of an .alpha./.beta.-hydrolase fold with a catalytic triad ((Ser/Cys)-(His)-(Asp/Glu/Ser)) for substrate binding and catalysis via a covalently bound peptide-thioesterase intermediate. Furthermore, TE domains were found to exist in two distinct conformations, the open and the closed state. Differences between both states are restricted to a region of 40 amino acid residues covering most of the active site of the enzyme, which was named the lid region.

[0021] Unlike many other catalytic domains involved in the biosynthesis of non-ribosomal peptides, TE domains are highly diverse and consequently no model exists for predicting TE loading or release selectivity (Horsman et al. 2015). Phylogenetic analysis of TE sequences show that they do not duster based on type of offloading chemistry they catalyze.

[0022] TE domains operate via a two-step mechanism, loading followed by release (Horsman et al. 2015). The active site Ser side chain alcohol is activated by the conserved His-Asp dyad, increasing its nucleophilicity. The T domain bound substrate approaches the activated Ser, mediated by the 4'Ppant cofactor. It has been hypothesized that the lid region opens to accommodate the presentation of thioester substrates. The deprotonated and conserved active site Ser attacks the substrate thioester and the resulting charged tetrahedral intermediate is stabilized in the oxyanion hole by hydrogen bonding from two backbone amide groups. This intermediate is resolved by loss of the 4'Ppant thiolate, generating the acyl-TE intermediate. The second step (offloading) involves release of the acyl group. This step begins with the approach of an intramolecular or intermolecular nucleophile. Townsend and colleagues (2010, 2014) suggested that the active-site histidinium ion is deprotonated by the departing thiolate and thus capable of activating the incoming nucleophile (Korman et al. 2010, Gaudelli and Townsend 2014). The nucleophile adds into the carbonyl of the acyl-TE intermediate and the tetrahedral intermediate is once again stabilized by the oxyanion hole. Finally the seryl alkoide is released with concerted protonation and the product leaves the active site.

[0023] Major insights into TE substrate specificity were gained by Trauger (2000) and Tseng (2002). By the use of synthetic SNAC-peptides (N-acetylcysteamin) they were able to show that TE domains are selective for the stereochemistry as well as the sidechain of the N-terminal AA residue. They also revealed that the AA next to the peptidyl-O-TE forming AA (C terminal AA) is important for peptide hydrolysis and cyclization, whereas all other AA within the produced peptide seem to be not crucial. Furthermore, Kohli et al. (2001) revealed that the excised TE domain from the tyrocidine NRPS accepts a broad spectrum of SNAC-peptides, varying in length and composition, as substrates for cyclization.

[0024] A noticeably distinct feature of most fungal NRPS is the replacement of the TE domain with a terminal C, Re, or T domain (Haynes et al. 2011). In addition to NAD(P)H-dependent Re domains, C domains can also be involved in peptide release (Kopp and Marahiel 2007). Whereas most bacterial NRPS use TE domains to perform the cyclization, fungal NRPS as well as some NRPS from bacteria including the genera Photorhabdus and Xenorhabdus use this complementary strategy (Gao et al. 2012; Reimer et al. 2013).

[0025] In macrocyclic fungal NRPSs such as cyclosporine A, aureobasidin A, apicidin and ferrichrome A, each corresponding NRPS catalyzes peptide release via terminal condensation (Cterm) domains (Gao et al. 2012). In the NRPS paradigm, C domains are canonically categorized to catalyze the formation of a peptide bond between the growing peptidyl-S-T.sub.n from module n and the activated aminoacyl-S-T.sub.n+1 using an active site histidine as the general base. Therefore, it is surprising that the Cterm domain is able to perform the equivalent head-to-tail linkage of a TE domain. The reaction relies on a serine residue of the highly conserved HHxxxDxxS motif in the active site for nucleophilic catalysis and the nucleophile is an intramolecular amino group, rather than the next AA (Kopp and Marahiel 2007). Gao et al. (2012) revealed that Cterm cyclization activity requires the presence of a T domain. Furthermore, via construction of recombinant T-Cterm didomains they were able to show that non-cognate T domains do not interact with the downstream Cterm domain. Therefore, protein-protein interactions between the Cterm and the upstream T domain seem to be specific and might rely on T domain sequence elements that are unique for recognition by C domains. However, although terminal C domains are cited as controlling the cyclization of NRPS-based intermediates, there is as yet no experimental evidence to illustrate their proposed catalytic activity (Haynes et al. 2011).

[0026] Besides Cterm domains that catalyze peptide release by cyclization, there are Cterm domains that catalyze the formation of an amide-bond between the linear T-domain bound peptide and an amine from the environment (Reimer et al. 2013; Fuchs et al. 2012, Gao et al. 2012, Cai et al. 2017). One example is the non-ribosomal rhabdopeptide biosynthesis cluster from Xenorhabdus nematophila. Here, the Cterm domain might be involved in the condensation of a biogenic amine (e.g., phenylethylamine derived from phenylalanine decarboxylation) with the peptide intermediate during the release process (Reimer et al. 2013; Fuchs et al., 2012).

[0027] Since 1995, when Marahiel et al. (WO200052152) were able to show that it is possible to recombine NRPS through exchanging adenylation-thiolation didomains, NRPS research came into focus (Marahiel et al. 1995). During the last two decades, there have been a lot of attempts to reprogram NRPS. Based on the crystal structure of the phenylalanine activating domain PheA (PDB-ID: 1AMU) Stachelhaus et al. were able to elucidate the specificity conferring AAs in the catalytic center (Conti et al. 1997, Stachelhaus et al. 1999). With this specificity conferring code, denoted as Stachelhaus-code it is possible to predict and to change substrate specificities of A domains in vitro, (Khurana et al. 2010, Rausch et al. 2005, Rottig et al. 2011, Kries et al. 2014). The most obvious disadvantage of this attempt is its inapplicability in vivo. One major reason for this drawback is that C and TE domains also have selectivities resulting in substrate incompatibilities (Belshaw et al. 1999; Trauger et al. 2000; Tseng et al. 2002).

[0028] A further attempt (WO200130985, Marahiel et al.) to vary known NRPS biosynthetic clusters is based on the exchange of single domains, didomains or whole modules and the knowledge of exactly defined borders (linkers) between individual domains. With this invention it was only possible to alter a few NRPSs successfully by introduction of additional modules or deleting them. However, it never was possible to produce totally artificial NRPSs from the artificial de novo combination of modules. This would result in new NRPS not present in nature that would also produce new peptides. The problem of such exchanges or combinations always was the uncertainty concerning the compatibility of modules and/or domains between each other. The shortcomings resulting from the lack of a solution to the problem mentioned above is illustrated by the fact that almost no artificial peptides have been designed by this approach.

[0029] Another attempt (WO2007014076, Walsh et al.) to vary known NRPS biosynthetic clusters is based on mutagenesis of so called "assembly lines" other word for synthases. Mutagenesis of genes of NRPS is not subject of the present invention although the present inventive methods can be combined with a mutagenesis that will alter the generated NRPS and cause altered peptide synthesis. This mutagenesis could be useful for increasing the diversification of NRPS libraries and the NRPS clone numbers in the library.

[0030] As A domains are the initial gatekeeping enzymes, the generation of modified peptide products requires substitution, or modification, of the A domain that specifies the target residue in the native peptide. There are three general strategies that researchers have employed to achieve this: (I) substitution of the A or paired A-T domain activating an alternative substrate; (II) targeted alteration of just the substrate binding pocket of the A domain; (III) substitutions that treat C-A or C-A-T domain units as inseparable pairs. These strategies are complemented by recombination studies which have sought to re-engineer NRPS by T, T-C-A, communication domain and A-T-C swapping. However, with exception of the latter and recently published strategy (Bozhuyuk et al. 2017), denoted as the concept of eXchange Units (XU), scientists have failed to introduce clearly defined, reproducible and validated guidelines for engineering modified NRPS (WO 2017/020983).

[0031] The XU-concept provides three simple rules for the design, cloning and production of NRPs of a desired AA composition, structure and length: (I) A-T-C or A-T-C/E are used as XUs, (II) XUs are fused in the C-A linker at the conserved WNATE sequence, and (III) the specificity of the downstream C domain must be respected. Applying XUs, naturally occurring NRPS assembly lines were reconstructed; new peptide derivatives and completely new artificial NP like peptides were produced. The disadvantage of the XU-concept is that the natural downstream C domain specificity must be obeyed clearly limiting its applicability and the C-domain specificities have to be met--at the donor as well as at the acceptor site. This disadvantage can be accepted if a large number of XUs with different downstream C domains are available. Due to these limitations also at least two XUs have to be exchanged to produce a new peptide derivative that differs in one AA position from the primary sequence of the wild type (WT) peptide. However, a more flexible system would be very desirable.

[0032] To be suited for broad application the drawbacks of the XU concept must be reduced. Therefore, the object of the present invention was to establish a more convenient method evading C-domain specificities. Such a method would drastically reduce the amount of NRPS building blocks necessary to produce or alter particular peptides and would enable the creation of artificial natural product libraries with hundreds or thousands of entities for bioactivity screenings.

[0033] The above problem is solved in a first aspect by a system for the production of a non-ribosomal peptide synthases (NRPS), wherein the system comprises at least one, preferably two, NRPS eXchange Units (XU.sub.2.0) each specific for a different or identical amino acid X for assembling an NRPS, and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (C.sub.Asub) specific for a given amino acid X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) specific for a given amino acid X, a condensation-domain donor site subdomain (C.sub.Dsub) specific for a given amino acid X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) specific for a given amino acid X.

[0034] In context of the present invention the designation "X" refers to an amino acid specificity of any NRPS module or exchange unit of the invention, for example a partial or complete C or C/E domain, or adenylation A domain. A specificity of such a domain or module may include specificity for one or more amino acid-species. For example, some domains (such as an A domain) have specificity for not only one single amino acid species, but for two, three, four or five or more different amino acid species. For example A domains have specificities for multiple amino acids that are also accepted by the downstream C or C/E domains resulting in the production of several different peptides. Therefore, the present invention also includes such domains which harbor specificity for multiple amino acid species.

[0035] The system of the invention preferably comprises an XU.sub.2.0 wherein the XU.sub.2.0 comprises at least one C or C/E domain which consists of only a partial sequence of said C or C/E domain, preferably which consists of only the donor or acceptor site of said C or C/E domain. In this respect an XU.sub.2.0 of the invention may comprise one partial C or C/E domain and optionally in addition one complete C or C/E domain, the latter comprising both C or C/E donor and acceptor sites. Hence, a XU.sub.2.0 of the invention is preferably characterized by the presence of at least one partial C or C/E domain. In some instances a system according to the invention may be preferred, wherein said at least one XU.sub.2.0 does not comprise a fully assembled C or C/E domain. However, a system of the invention may preferably comprise more than one XU.sub.2.0, and therefore may comprise both XU.sub.2.0 wherein only partial C or C/E domains are present, and XU.sub.2.0 wherein one complete C or C/E domain is comprised, and in addition, optionally, may comprise additional NRPS exchange units which do not comprise a partial C or C/E domain. Hence, a system of the invention at least comprises one XU.sub.2.0, in some embodiments in combination with (i) other one or more XU.sub.2.0, and/or (ii) other prior art exchange units, and/or (iii) other natural occurring NRPS sequences. In addition thereto, the system of the invention may also include exchange units for or derived from PKS.

[0036] For the present invention, the following definitions shall be used:

[0037] The term "partial domain" or "partial C or C/E domain" or similar expression shall refer to nucleic acid sequence encoding for, or a protein sequence of, an NRPS C or C/E domain which is incomplete (not full length). The term therefore describes a C or C/E domain sequence which does not comprise both donor and acceptor sites of an NRPS C or C/E domain.

[0038] By "assembly" is meant a set of domains. A plurality of assembly comprises an NRPS. One or more polypeptides may comprise a module. Combinations of modules can catalyze a series of reactions to form larger molecules. In one example, a module may comprise a C (condensation) domain, an A (adenylation) domain, and a peptidyl carrier protein domain.

[0039] For more structural information on A domains, C domains, didomains, domain-domain interfaces and complete modules see Conti et al. (1997), Sundlov et al. (2013), Samel et al. (2007), Tanovic et al. (2008), Strieker and Marahiel (2010), Mitchell et al. (2012) and Tan et al. (2015).

[0040] By "initiation module" is meant a N-terminal module which is capable of providing a first monomer to another module (e.g., an elongation or termination module). In some instances the other module is not the second but any of the C-terminally following modules (as is the case for the Nocardicin NRPS): In the case of an NRPS, an initiation module comprises, for example, an A (adenylation) domain and a PCP (peptidyl carrier protein) or T (thiolation) domain. The initiation module may also contain a starter C domain and/or an E (epimerization) domain. In the case of a PKS, a possible initiation module comprises an AT (acetyltransferase) domain and an acyl carrier protein (ACP) domain. Initiation modules are preferably at the amino terminus of a polypeptide of the first module of an assembly line, and each assembly line preferably contains one initiation module.

[0041] By "elongation module" is meant a module which adds a monomer to another monomer or to a polymer. An elongation module may comprise a C (condensation), Cy (heterocyclization), E, C/E, MT (methyltransferase), A-MT (combined adenylation and methylation domain), Ox (oxidase), or Re (reductase) domain; an A domain; or a T domain. An elongation domain may further comprise additional E, Re, DH (dehydration), MT, NMet (N-methylation), AMT (Aminotransferase), or Cy domains. Additionally, an elongation module might be of PKS origin comprising the respective domains (ketosynthase (KS), acyltransferase (AT), ketoreductase (KR), dehydratase (DH), enoylrductase (ER, thiolation (T)) connecting an amino acid building block with a carboxylic acid building block.

[0042] By "termination module" is meant a module that releases the molecule (e.g., an NRP, PK, or combination thereof) from the assembly line. The molecule may be released by, for example, hydrolysis or cyclization. Termination modules may comprise a TE (thioesterase), C.sub.term, or Re domain. The termination module is preferably at the carboxy terminus of a polypeptide of an NRPS or PKS. The termination module may further comprise additional enzymatic activities (e.g., oligomerase activity).

[0043] By "domain" is meant a polypeptide sequence, or a fragment of a larger polypeptide sequence, with one or more specific enzymatic activities (i.e. C/E domains have a C and a E function in one domain) or another conserved function (i.e. as tethering function for an ACP or T domain). Thus, a single polypeptide may comprise multiple domains. Multiple domains may form modules. Examples of domains include C (condensation), Cy (heterocyclization), A (adenylation), T (thiolation), TE (thioesterase), E (epimerization), C/E (condensation/epimerization), MT (methyltransferase), Ox (oxidase), Re (reductase), KS (ketosynthase), AT (acyltransferase), KR (ketoreductase), DH (dehydratase), and ER (enoylreductase).

[0044] By "non-ribsomally synthesized peptide," "non-ribosomal peptide," or "NRP" is meant any polypeptide not produced by a ribosome. NRPs may be linear, cyclized or branched and contain proteinogenic, natural or non-natural amino acids, or any combination thereof. NRPs include peptides produced in an assembly line like manner (=modular character of the enzyme system allowing a stepwise addition of building blocks to form a final product).

[0045] By "polyketide" is meant a compound comprising multiple ketyl units.

[0046] By "non-ribosomal peptide synthetase" or "non-ribosomal peptide synthase" or "NRPS" is meant a polypeptide or series of interacting polypetides that produce a nonribosomal peptide, thus that is able to catalyze peptide bond formation without the presence of ribosomal components.

[0047] By "polyketide synthase" (PKS) is meant a polypeptide or series of polypeptides that produce a polyketide. By "alter an amount" is meant to change the amount, by either increasing or decreasing. An increase or decrease may be by 3%, 5%, 8%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more.

[0048] By "non-ribosomal peptide synthetase/polyketide synthase hybrid" or hybrid of non-ribosomal peptide synthetase and polyketide synthase" or "NRPS/PKS hybrid" or "hybrid of NRPS and PKS" or "hybrid of PKS and NRPS" is meant a enzyme systems comprising any domains or modules from non-ribosomal peptide synthetases and polyketide synthases resulting in the respective hybrid natural products.

[0049] By "altering a structure" any change in a chemical (e.g., covalent or noncovalent) bond as compared to a reference structure is meant.

[0050] By "mutation" an alteration in the nucleic acid sequence such that the amino acid sequence encoded by the nucleic acid sequence has at least one amino acid alteration from a naturally occurring sequence is meant. The mutation may, without limitation, be an insertion, deletion, frameshift mutation, or a missense mutation. This term also describes a protein encoded by the mutant nucleic acid sequence.

[0051] By "variant" a polypeptide or polynucleotide with at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% sequence identity to a reference sequence is meant. Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications by applying substitution/scoring matrices (e.g. PAM, Blosum, GONET, JTT). Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e-3 and e-150 indicating a closely related sequence (Altschul et al., 1990).

[0052] In some embodiments, the system according to the invention is preferred, wherein at least one XU.sub.2.0 comprises a C- or C/E acceptor domain and a C- or C/E donor domain separated by one or more NRPS domains other than C or C/E domains. In this embodiment, each single unit consists of one C- or C/E acceptor domain and one C- or C/E donor domain separated by a non-C or non-C/E domain, preferably separated by an adenylation A domain. In other embodiments, the system is preferred wherein each unit within the system comprises (i) only one C- or C/E acceptor domain or only one C- or C/E donor domain; or (ii) comprises only C- or C/E acceptor domain and only one C- or C/E donor domain, wherein the two domains are spatially separated by one or more other NRPS domains.

[0053] Preferably an XU.sub.2.0 of the invention comprises at least the following structure: Z.sup.XY.sup.X or Y.sup.XZ.sup.X; wherein Z is a partial C or C/E domain, preferably C(or C/E).sub.Asub or C(or C/E).sub.Dsub.sup.X, and wherein Y is any one or multiple identical or different (or both) NRPS/PKS domain(s) or module(s) having a similar or identical specificity X, wherein X stands for an amino acid specificity of the domain or module to one or more amino acid species. In addition the XU.sub.2.0 may comprise additional modules or domains at either N or C terminal end.

[0054] In other preferred alternative or additional embodiments of the invention, at least one XU.sub.2.0 has a structure according to any one of the following formulas:

C.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X, a.

C/E.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X, b.

C.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dusb.sup.X, c.

or

C/E.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X, d.

[0055] Additional units comprised in the system of the invention may be selected from one or more of the following formulas:

C.sup.X-A.sup.X-T-C.sub.Dsub.sup.X e.

C/E.sup.X-A.sup.X-T-C.sub.Dsub.sup.X f.

C.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X g.

C/E.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X h.

C.sub.Asub.sup.X-A.sup.X-T-C.sup.X i.

C/E.sub.Asub.sup.X-A.sup.X-T-C/E.sup.X j.

C.sub.Asub.sup.X-A.sup.X-T-C/E.sup.X k.

C/E.sub.Asub.sup.X-A.sup.X-T-C.sup.X l.

C.sub.start-A.sup.X-T-C.sub.Dsub.sup.X, m.

A.sup.X-T-C.sub.Dsub.sup.X, n.

C.sub.start-A.sup.X-T-C/E.sub.Dsub.sup.X o.

A.sup.X-T-C/E.sub.Dsub.sup.X, p.

C.sub.Asub.sup.X-A.sup.X-T-TE q.

C/E.sub.Asub.sup.X-A.sup.X-T-TE r.

C.sub.Asub.sup.X-A.sup.X-T-C.sub.term s.

C/E.sub.Asub.sup.X-A.sup.X-T-C.sub.term t.

C.sub.Asub.sup.X-Y.sup.X-C.sub.Dsub.sup.X u.

C/E.sub.Asub.sup.X-Y.sup.X-C/E.sub.Dsub.sup.X v.

C.sub.Asub.sup.X-Y.sup.X-C/E.sub.Dsub.sup.X w.

C/E.sub.Asub.sup.X-Y.sup.X-C.sub.Dsub.sup.X x.

C.sup.X-Y.sup.X-C.sub.Dsub.sup.X y.

C/E.sup.X-Y.sup.X-C.sub.Dsub.sup.X z.

C.sup.X-Y.sup.X-C/E.sub.Dsub.sup.X aa.

C/E.sup.X-Y.sup.X-C/E.sub.Dsub.sup.X bb.

C.sub.Asub.sup.X-Y.sup.X-C.sup.X cc.

C/E.sub.Asub.sup.X-Y.sup.X-C/E.sup.X dd.

C.sub.Asub.sup.X-Y.sup.X-C/E.sup.X ee.

C/E.sub.Asub.sup.X-Y.sup.X-C.sup.X ff.

C.sub.start-Y.sup.X-C.sub.Dsub.sup.X, gg.

C.sub.start-Y.sup.X-C/E.sub.Dsub.sup.X hh.

Y.sup.X-C.sub.Dsub.sup.X ii.

Y.sup.X-C/E.sub.Dsub.sup.X jj.

C.sub.Asub.sup.X-Y.sup.X-TE kk.

C/E.sub.Asub.sup.X-Y.sup.X-TE ll.

C.sub.Asub.sup.X-Y.sup.X-C.sub.term mm.

C/E.sub.Asub.sup.X-Y.sup.X-C.sub.term nn.

wherein C.sub.Asub.sup.X or C/E.sub.Asub.sup.X are C.sub.Asub or C/E.sub.Asub have the amino acid specificity X, and X is a specificity to one or more amino acid species for example to amino acids X1-Xn, Y.sup.X epresents one or a sequential series of any NRPS or PKS domains or modules (e.g. A, T, E, C, MT, A-MT, Cy) having the amino acid specificity X, A.sup.X are adenylation domains having the amino acid specificity X, C or C/E are C or C/E having the amino acid specificity X, C.sub.Dsub.sup.X or C/E.sub.Dsub.sup.X are D.sub.Dsub or a C/E.sub.Dsub have the amino acid specificity X, and TE are thioesterase domains and C.sub.term are terminal Condensation domains, both relevant for NRPS regeneration.

[0056] In some embodiments of the invention an XU.sub.2.0 of a system of the invention may include domains with promiscuous amino acid specificity.

[0057] In some embodiments of the invention an XU.sub.2.0 of a system of the invention may include domains with different amino acid specificity. Hence, the amino acid specificity of the partial C or C/E subdomains may differ from another and/or from the A domain of the same unit. However, it is generally preferred that an XU.sub.2.0 of the invention comprises domains and modules with identical or at least overlapping amino acid specificities X. Of course this does not exclude, to the contrary this is intended according to the invention, that the system includes multiple XU.sub.2.0 having different amino acid specificities X in order assemble a non ribosomal peptide with different amino acid residues.

[0058] The domain abbreviations are defined above. For the contest of the present invention the index .sub.Dsub shall refer to a C or C/E donor subdomain, and .sub.Asub shall refer to a C or C/E acceptor subdomain. The X shall denote the amino acid specificity of the respective domain.

[0059] In this context it is noted than X may be selected from any natural or non-natural occurring amino acid. Also within the system, each unit in the system may have a different given amino acid X, or a given amino acid X which is identical with one or more other exchange units in the system.

[0060] In other embodiments each single XU.sub.2.0 preferably does not comprise a functionally assembled condensation (C)- or condensation/epimerization (C/E)-domain. Using the system of the invention, only the assembly of two individual XU.sub.2.0 will result in a functional C or C/E domain.

[0061] In other embodiments the system preferably includes at least two XU.sub.2.0, when connected to each other, form a functional assembled C or C/E domain composed of one partial C or C/E domain of the first XU.sub.2.0 and one partial C or C/E domain of the second XU.sub.2.0. Preferably the partial domains of the first and the second XU.sub.2.0 are different in kind, in other words, are preferably either a donor or an acceptor domain.

[0062] Yet another preferred embodiment of the invention provides a system, comprising at least two XU.sub.2.0 of which each has specificity for a different amino acid X, preferably wherein each X is selected from any natural or non-natural amino acid.

[0063] In accordance with the present invention the amino acid X is selected from a proteinogenic amino acid, a non-proteinogenic amino acid, a D- or L-amino acid, or a non-standard amino acid, or combinations thereof.

[0064] Furthermore, the invention provides in some embodiments a system further comprising a XU.sub.2.0 termination and/or initiation unit, wherein the XU.sub.2.0 initiation unit comprises only a C or C/E domain donor subdomain, a domain structure C-A.sup.X-T-C.sub.Dsub.sup.X or C-A.sup.X-T-C/E.sub.Dsub.sup.X, specific for the incorporation of acyl units (fatty acids and their derivatives) as starting units, and wherein the termination module comprises any one of a terminal condensation domain (C.sub.term), an internal condensation (C) domain, an internal condensation and epimerization (C/E)-didomain, a cyclization (Cy) domain, an epimerization (E) domain, a reduction (Re), an oxidation (Ox) or a thioesterase (TE) domain.

[0065] For example, in some embodiments the system preferably comprises an XU.sub.2.0 initiation unit having any one of the following formulas:

C.sub.Asub-A.sup.X-T-C.sub.Dsub.sup.X,

C/E.sub.Asub-A.sup.X-T-C.sub.Dsub.sup.X,

C.sub.Asub-A.sup.X-T-C/E.sub.Dsub.sup.X,

C/E.sub.Asub-A.sup.X-T-C/E.sub.Dsub.sup.X,

or

C.sub.start-A.sup.x-T-C.sub.Dsub.sup.X,

A.sup.X-T-C.sub.Dsub.sup.X,

C.sub.start-A.sup.X-T-C/E.sub.Dsub.sup.X,

or

A.sup.x-T-C/E.sub.Dsub.sup.X,

where instead of a C.sub.Asub or a C/E.sub.Asub domain also a complete C.sub.start or C or no C domain of any kind may be present.

[0066] The system of the invention preferably has at least two, preferably three, four, or more, XU.sub.2.0 when put into sequence provide the NRPS. The number of units is not in any way limited and will dependent on the intended complexity of the system or on the peptides to be produced. Systems may include at least 2, 5, 10, 20, 30, 40, 50, 100, 500, or more units. And the units may have identical or different amino acid specificities X.

[0067] Any two XU.sub.2.0 of the present invention can be assembled at the loop region between the C- or C/E-domain donor and acceptor sites. The loop region is the region in a C or C/E domain which connects the two halves of the pseudo dimer structure of the C or C/E domain (Keating et al. 2002, Samel et al. 2007, Tanovic et al. 2008, Bloudoff et al. 2013). Preferably the loop region is between amino acid 261 and 271--according to the nomenclature of the crystal structure of the TycC5-6 T-C didomain (PDB-ID: 2JGP)--for a C or C/E domain.

[0068] In some additional embodiments the system of the invention may include at least one XU.sub.2.0 having a modification domain, such as an E, MT or Ox or other modification domain.

[0069] The system of the invention in some embodiments may be a system, wherein each XU.sub.2.0 is encoded by a sequence of nucleic acids. The system is therefore a system of nucleic acid constructs. In other embodiments, the system is a system of a sequence of amino acids or proteins, such as NRPS.

[0070] Further preferred is a system comprising for each amino acid X each of the following XU.sub.2.0 of the formula: C.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X, C/E.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X, C.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X, C/E.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X.

[0071] The system according to the invention may comprise said XU.sub.2.0 for two or more amino acids X, preferably for a multitude of amino acids, preferably wherein the system comprises for each natural amino acid one of C.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X, C/E.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X, C.sub.Asub.sup.X-A.sup.X-T-C/E.sub.Dsub.sup.X, and C/E.sub.Asub.sup.X-A.sup.X-T-C.sub.Dsub.sup.X.

[0072] In another aspect of the invention a method for the production of peptides is provided comprising a step of expressing or assembling a NRPS assembled with a system according to the present invention.

[0073] In another aspect of the invention a library of nucleic acid molecules is provided, wherein the library comprises at least two or more nucleic acid constructs each encoding an XU.sub.2.0, and each having the same or different amino acid specificities and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (C.sub.Asub) having an amino acid specificity X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) having an amino acid specificity X, a condensation-domain donor site subdomain (C.sub.Dsub) having an amino acid specificity X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) having an amino acid specificity X. Said XU.sub.2.0 may in some embodiments not comprise a fully assembled C or C/E domain.

[0074] The library of the invention may comprise nucleic acid constructs encoding at least one XU.sub.2.0 termination and/or initiation unit, wherein the XU.sub.2.0 initiation unit comprises only a C or C/E domain donor subdomain, a domain structure C-A.sup.X-T-C.sub.Dsub.sup.X or C-A.sup.X-T-C/E.sub.Dsub.sup.X, specific for the incorporation of acyl units (fatty acids and their derivatives) as starting units, and wherein the termination module comprises any one of a terminal condensation domain (Cterm), an internal condensation (C) domain, an internal condensation and epimerization (C/E)-didomain, a cyclization (Cy) domain, an epimerization (E) domain, a reduction (R), an oxidation (Ox) or a thioesterase (TE) domain

[0075] The library of the invention may be preferred, wherein each XU.sub.2.0 is encoded by a separate nucleic acid construct. Preferably the library comprises the XU.sub.2.0 of the system described herein before.

[0076] A method for producing a NRPS, the method comprising a step of assembling at least two NRPS eXchange Units (XU.sub.2.0) each specific for a different or identical amino acid X, and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (C.sub.Asub) specific for a given amino acid X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) specific for a given amino acid X, a condensation-domain donor site subdomain (C.sub.Dsub) specific for a given amino acid X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) specific for a given amino acid X; wherein said XU.sub.2.0 does not comprise a fully assembled C or C/E domain. Preferably the NRPS is assembled out of the nucleic acid constructs of the library of the invention, and expression of said NRPS.

[0077] In addition there is provided a method for the production of non-ribosomal peptides having a specific sequence, the method comprising assembling a NRPS according to the method for producing a NRPS of the invention, wherein the NRPS is composed of a sequence of XU.sub.2.0 having specificity according to the peptide to be produced.

[0078] A further aspect of the invention then provides a biological cell comprising a nucleic acid construct as described before in context of the library of the invention Therefore, the invention may also provide as one aspect a library of biological cells (strains), wherein each biological cell (strain) comprises a nucleic acid construct of the above described library.

[0079] The non-ribosomal peptide of the invention may be a linear or a cyclic peptide. When the peptide is cyclic, the NRPS preferably comprises a cyclization domain in the termination module (i.e. thioesterase (TE), reductase (Red), terminal condensation (Cterm) or C/E domain). Non-ribosomal peptides produced according to the descriptions of the invention are preferably non-naturally occurring non-ribosomal peptides.

[0080] Another aspect of the invention then pertains to a method for modifying a provided NRPS-encoding sequence, the method comprising the steps of providing a NRPS-encoding sequence, preferably a full length NRPS-encoding sequence such as a wild type or naturally occurring NRPS-encoding sequence, and introducing into said NRPS-encoding sequence a XU.sub.2.0 as defined by the present invention, to preferably replace and/or complement the respective domains of the provided NRPS with the domains encoded by the XU.sub.2.0. The replacement is preferably to modify the sequence or structure of the peptide product produced by the NRPS. XU.sub.2.0 of the invention may be used to introduce additional one or more amino acids, to remove one or more amino acids, to replace one or more amino acids, and/or to change the peptide structure (cyclic or linear peptides). The introduction of the XU.sub.2.0 of the invention in the method is preferably done by fusing XU.sub.2.0 fragments encoding a donor or acceptor site of a partial C or C/E domain of the XU.sub.2.0 to a corresponding end of a donor or acceptor site of the provided NRPS-encoding sequence, to thereby obtain a chimeric C or C/E domain of the introduced XU.sub.2.0 and the provided NRPS.

[0081] The present invention will now be further described in the following examples with reference to the accompanying figures and sequences, nevertheless, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties. In the Figures:

[0082] FIG. 1: Modulation of C-domain substrate specificity. (a) C-domain excised from the T-C bidomain TycC 5-6 from tyrocidine syntethase (TycC) of Brevibacillus brevis (PDB-ID: 2JGP) with N-terminal (yellow) and C-terminal (blue) subdomains depicted in ribbon representation (top). Boxed: enlarged representation of the C.sub.Dsub-C.sub.Asub linker with contributing linker AAs in stick representation and fusion site marked in red. Bottom: sequence logo of C.sub.Dsub-C.sub.Asub linker sequences from Photorhabdus and Xenorhabdus. (b) Schematic representation of WT GxpS, recombinant NRPS-1 and -2 as well as corresponding peptide yields as obtained from triplicate experiments. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. (c) Schematic representation of BicA with modules and eXchange Units (XU and XU.sub.2.0) highlighted. Specificities are assigned for all A-domains. For domain assignment the following symbols are used: A (large circles), T (rectangle), C (triangle), C/E (diamond), TE (C-terminal small circle).

[0083] FIG. 2: De novo design of recombinant NRPS for peptide production. (a) Generated recombinant GxpS (NRPS-3-5) and corresponding amounts of GameXPeptide derivatives 1, 3, 6, and 7 as determined in triplicates. (b) Recombinant NRPS-6 synthesizing 8. Building blocks are of Gram-positive origin. Bottom: Color code of NRPS used as building blocks (for details see FIG. 8). For assignment of domain symbols see FIG. 1.

[0084] FIG. 3: Exchange of NRPS starter units. Schematic representation of recombnant GxpS (NRPS-7-9) and corresponding peptide yields as obtained from triplicate experiments. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. For assignment of domain symbols see FIG. 1. Bottom: Color code of NRPS used as building blocks (for details see FIG. 8).

[0085] FIG. 4: Creation of functionalized xenotetrapeptide derivatives. Schematic representation of WT XtpS, recombinant NRPS-10 and corresponding peptide yields as obtained from triplicate experiments. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. For assignment of domain symbols see FIG. 1. Bottom: Color code of NRPS used as building blocks (for details see FIG. 8).

[0086] FIG. 5: Targeted randomization of GxpS at position three. Schematic representation of all possible recombinant NRPSs (top left) and corresponding A domain specificity (bottom left). Detected peptides (solid line) and corresponding peptide yields (top right) as obtained from triplicate experiments. Dashed lines indicate not determined GxpS derivatives. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. For assignment of domain symbols see FIG. 1. Bottom: Color code of NRPS used as building blocks (for details see FIG. 8).

[0087] FIG. 6: The creation of a library with randomization of position one and three from GxpS. Schematic representation of all possible recombinant NRPSs (top left) and corresponding A domain specificity (bottom left). Detected peptides and corresponding peptide yields (right) as obtained from triplicate experiments. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. For assignment of domain symbols see FIG. 1. Bottom Color code of NRPS used as building blocks (for details see FIG. 8).

[0088] FIG. 7: Randomization of adjacent positions. (a) Crystal structure of TycC6 (PDB-ID: 2JGP), subdivided into N terminal subdomain (grey) and C terminal subdomain (light red). The subdomain linker is highlighted in red and the targeted area (I253-F265) for homologues recombination in yeast is highlighted in green (39 nucleotides). The Consensus sequence used to generate library three is shown bottom right. (b) Schematic representation of all possible recombinant NRPSs (top left) and corresponding A domain specificity (bottom left). Detected peptides and corresponding peptide yields (right) as obtained from triplicate experiments. For peptide nomenclature the standard one letter AA code with lowercase for D-AA is used. For assignment of domain symbols see FIG. 1. Bottom right: Color code of NRPS used as building blocks (for details see FIG. 8).

[0089] FIG. 8: Schematic overview of all NRPS used in this work. GxpS, BicA, XtpS, HCTA, PaxB, KolS, AmbS.sub.mir from X. miraniensis and AmbS.sub.ind from X. indica have been described previously. For GarS producing gargantuanin see Genbank accession number PRJNA224116. For Xenolindicin-like syntethase see Genbank accession number PRJNA328553. For XeyS producing xindeyrin see Genbank accession number PRJNA328572.

EXAMPLES

Example 1: C-Domains Have Acceptor Site Substrate Specificity

[0090] To verify the influence of the C-domains acceptor site (C.sub.Asub) proof reading activity, GameX-Peptide producing NRPS GxpS of Photorhabdus luminescens TT01 was chosen as a model system (Bode et al. 2012; Nollmann et al. 2014). A recombinant GxpS was constructed, not complying with the rules of the XU concept (WO 2017/020983). Here, XU2 of GxpS (FIG. 1b, NRPS-1) was exchanged against XU2 of the bicornutin producing NRPS (BicA, FIG. 1c) (Fuchs et al. 2012). Although both XUs are Leu specific, they are differentiated by their C.sub.Asub specificities--Phe for XU2 of GxpS and Arg for XU2 of BicA. Therefore, no peptide production was observed as expected. This experiment confirmed previously published scientific results from in vitro experiments (Belshaw et al. 1999, Clugston et al. 2003, Samel et al. 2007, Rausch et al. 2007), and illustrates that C-domains indeed are highly substrate specific at their C.sub.Asub (WO 2017/020983).

Example 2: Modulation of C-Domain Substrate Specificity

[0091] In developing a new and C-domain specificity independent and/or evading strategy, the inventors strived to determine the structural basis for this purpose by reviewing available structural data of C-domains (Samel et al. 2007, Tanovic et al. 2008). As C-domains have a pseudo-dimer configuration (Keating et al. 2002, Samel et al. 2007, Tanovic et al. 2008, Bloudoff et al. 2013), and the catalytic center, including the HHXXXDG motif, has two binding sites--one for the electrophilic donor substrate and one for the nucleophilic acceptor substrate (Rausch et al. 2007) (FIG. 1a)--the inventors concluded that the four AA long conformationally flexible loop/linker between both subdomains might be the ideal target to reconfigure C-domain specificities, by engineering C-domain hybrids (FIG. 1a). For this purpose the Arg specific C.sub.Asub of the GxpS-BicA hybrid NRPS (FIG. 1b, NRPS-1) was re-exchanged to the Leu specific C.sub.Asub of GxpS, restoring the functionality of the hybrid NRPS (NRPS-2) and leading to the production of GameXPeptide A-D (1-5) in 217% yield compared to the WT GxpS (FIG. 1b) confirmed by MS/MS analysis and comparison of the retention times.

Example 3: The eXchange Unit 2.0

[0092] From above mentioned results in conjunction with bioinformatics analysis, the inventors concluded that C-domains acceptor and donor site (C.sub.Dsub) mark a self-contained catalytically active unit C.sub.Asub-A-T-C.sub.Dsub (XU.sub.2.0)--without interfering major domain-domain interfaces/-actions during the NRPS catalytic cycle (Marahiel 2015). In order to validate the proposed XU.sub.2.0 building block (FIG. 1c) and to compare the production titers with a natural NRPS, the inventors reconstructed GxpS (FIG. 1b) in two variants (FIG. 2, NRPS-3 and -4). Each from five XU.sub.2.0 building blocks from four different NRPSs (XtpS, AmbS, GxpS, GarS, HCTA) (FIG. 8):

[0093] NRPS-3: although leading to a mixed C/E.sub.Dsub-C.sub.Asub-domain between XU.sub.2.03 and XU.sub.2.04 (FIG. 2), XU.sub.2.0 building blocks from XtpS (XU.sub.2.01), AmbS (XU.sub.2.04), GxpS (XU.sub.2.03 and 5), and GarS (XU.sub.2.04) were used, to reveal if C and C/E domains can be combined.

[0094] NRPS-4: to prevent any incompatibilities, XU.sub.2.03 originated from GarS was replaced by a XU.sub.2.03 from HCTA (FIG. 2).

[0095] Whereas NRPS-3 (FIG. 2) showed no detectable production of any peptide, NRPS-4 (FIG. 2) resulted in the production of 1 and 3 in 66 and 6% yield compared to the natural GxpS, as confirmed by MS/MS analysis and comparison of the retention times (FIG. 2,). In line with expectations from domain sequences, phylogenetics as well as structural idiosyncrasies of C/E- and C-domains (Rausch et al. 2007), it may be deduced from these results that C/E and C-domains cannot be combined with each other. Although NRPS-4 (FIG. 2) showed moderately reduced production titers, most likely due to the non-natural C.sub.Dsub-C.sub.Asub pseudo-dimer interface, the formal exchange of the non-specific XU.sub.2.01 from GxpS (Val/Leu) against the Val-specific XU.sub.2.01 from XtpS led to exclusive production of 1 and 3 without production of 2 and 4 (FIG. 2), indicating that the XU.sub.2.0 can also be used for increasing product specificity and reducing side products (WO 2017/020983).

[0096] Additional GameXPeptide derivatives were generated (FIG. 2a, NRPS-5) by combining building blocks according to the definition of XU and XU.sub.2.0 (WO 2017/020983). Three fragments (1: C1-A1-T1-C/E2 of BicA; 2: A2-T2-C3-A3-T3-C/E4-A4-T4-C/E.sub.Dsub5 of GxpS; 3: C/E.sub.Asub5-A5-T5-C.sub.term of BicA) from two NRPSs (BicA: Xenorhabdus budapestensis DSM 16342; GxpS: Photorhabdus luminescens TT01) were used as construction material (Bode et al. 2012, Fuchs et al. 2012). The expected two Arg containing cyclic pentapeptides 6 and 7 were produced in yields of 2.25 and 0.17 mg/L and were structurally confirmed by chemical synthesis. Both peptides only differ in Leu or Phe at position three from the relaxed substrate specificity of XU.sub.2.03 from GxpS. Despite a drop of production rate in comparison to the WT NRPS, the inventors successfully demonstrated that the recently published XU (WO 2017/020983) as well as the novel XU.sub.2.0 reliably broaden the possibilities of successfully reprogramming NRPS and to heterologously synthesize tailor-made peptides.

[0097] To show the general applicability of the novel XU.sub.2.0 building block an artificial NRPS was designed de novo from building blocks of Gram-positive origin (NRPS for the production of bacitracin (Konz et al. 1998) from Bacillus licheniformis ATCC 10716 and surfactin (Cosmina et al. 1993) from Bacillus subtilis MR 168), since all aforementioned recombined NRPS are of Gram-negative origin. The expected pentapeptide (8) containing the bacitracin NRPS derived thiazoline ring was produced in yields of 21.09 mg/L (FIG. 2b), showing the universal nature of the XU.sub.2.0.

Example 4: Amending the Starter Unit

[0098] Up to date there is no publication describing the successful exchange of a starter unit against an internal module NRPS-fragment. However, possible identified problems which would need to be solved for example are: (I) as starter-A-domains in general comprise some kind of upstream sequence of variable length with unknown function and structure, it is difficult to define an appropriate artificial leader sequence, and (II) necessary interactions at the C-A interface may be important for adenylation activity and A-domain stability, like indicated by recently published studies (Li et al. 2016, Meyer et al. 2016). Therefore, the first step in order to approach the concrete problem three recombinant GxpS constructs (NRPS-7-9) with internal domains as starting units were created (FIG. 3):

[0099] NRPS-7: as all starter A-domains have at least a preceding C-A linker sequence A1-T1-C.sub.Dsub2 of GxpS was exchanged against C2A3-linker-A3-T3-C.sub.Dsub4 of XtpS;

[0100] NRPS-8: as there are several examples of NRPS carrying parts of a C-domain (e.g. BicA) in front of the starter A-domain A1-T1-C.sub.Dsub2 of GxpS was exchanged against C.sub.Asub-A3-T3-C.sub.Dsub4 of Xtps;

[0101] NRPS-9: as there are biosynthetic templates available, exhibiting catalytically inactive starter C-domains (e.g. AmbS), A1-T1-C.sub.Dsub2 of GxpS was altered to C3-A3-T3-C.sub.Dsub4 of XtpS.

[0102] Whereas NRPS-7 (FIG. 3) did not show production of the desired peptides, NRPS-8 synthesized 1-3 in yields of 0.35 and 0.44 mg/L, and NRPS-9 produced 1 in yields of 0.31 and 0.34 mg/L, as confirmed by MS/MS analysis and comparison of the retention times (FIG. 3). Obtained results revealed that internal A-domains can be used as starter domains, if the upstream C.sub.Asub or C-domain is kept in front of the A-domain--indicating the importance of a functional C-A interface for A-domain activity. Yet, from drop in production titers, further questions arise that must be answered by future work. One reason for decreased synthesis rates might be for example the observed codon usage and the lowered GC-content at the beginning of WT NRPS encoding genes, which can have a major impact on transcriptional and/or translational efficiency in conjunction with protein folding issues.

Example 5: The Creation of Functionalized Peptides

[0103] Besides simply creating NRP derivatives, one useful application of NRPS reprogramming is the incorporation of AAs that contain alkyne or azide groups into peptides, allowing reactions like Cu(I)-catalyzed or strain-promoted Huisgen cyclization--also known as "click" reactions (Sletten & Bertozzi 2009; Kolb & Sharpless 2003). Yet, although NPRS and A domains have been examined exhaustively for several years, no general method for the simple functionalization of NRPs has emerged.

[0104] A broad range of AAs are accepted by the A3 domain of GxpS resulting in a large diversity of GameXPeptides (Bode et al. 2012, Nollmann et al. 2014). Moreover, by using a .delta.-.sup.18O.sub.4-ATP pyrophosphate exchange assay for adenylation activity (Phelan et al. 2009, Kronenwerth et al. 2014) and adding substituted AAs to growing E. coli cultures expressing GxpS, the respective A3-domain was identified as being able to activate (in vitro) and incorporate (in vivo 10) several ortho- (o), meta- (m) and para- (p) substituted phenylalanine derivatives, including 4-azido-L-phenylalanine (p-N.sub.3-Phe) and O-propargyl-L-tyrosine (Y-Tyr).

[0105] In order to create functionalized NRPs the Val specific XU.sub.2.03 of the xenotetrapeptide (Kegler et al. 2014) (9) producing NRPS (XtpS) from X. nematophila HGB081 was exchanged against XU.sub.2.03 of GxpS, resulting in the production of six new xenotetrapeptide derivatives (10-15) in yields of 0.17-106 mg/L (FIG. 4). After adding p-N.sub.3-Phe and Y-Tyr to growing E. coli cultures expressing recombined XtpS (NRPS-10), six functionalized peptides (16-21) have been identified in yields of 5-228 mg/L. Compounds 17, 8 and 19 were structurally confirmed by chemical synthesis. Due to the relaxed substrate specificity of the introduced A3-domain, compounds 9-21 differ at position three. Moreover, although the A4-domain of XtpS shows an exclusive specificity for Val in the WT NRPS, peptides 11, 13, 16 and 21 produced by NRPS-10 additionally differ in Val or Leu at position four. The observed specificity shift might be due to the hybrid C/E4-domain upstream of A4 from NRPS-10. Leu is the original substrate downstream of the introduced XU.sub.2.03 of GxpS (FIG. 1b) in its natural context, indicating that the overall structure of C-domain's along with resulting transformed C-A interface interactions might have some kind of influence to A-domain's substrate specificity. Recently, similar but in vitro observed effects were reported regarding A-domains from sulfazecin (Li et al. 2016) and microcystin (Meyer et al. 2016). This effect could also be used to increase the specificity of A-domains to prevent the formation of side products. Further investigations will shed light on this remarkable and yet unreported effect.

Example 6: The Biotechnological Creation of Natural Product Like Peptide Libraries

[0106] To address the issue of biologically relevant chemical space the modern drug-discovery approach applies screening libraries based on NPs (Harvey et al. 2015). NP collections exhibit a wide range of pharmacophores, a broad range of stereochemistry and have the property of metabolite-likeness providing a high degree of bioavailability. Yet, the NP discovery process is as expansive as time consuming (Lefevre et al. 2008). Consequently, for bioactivity screenings the random recombination of certain NRPS fragments would be a powerful means to create focused artificial NP-like libraries. The definition of XU.sub.2.0 building blocks, including the targeted and automated reprograming of C-domain specificities, brought this goal within grasp.

[0107] For an initial approach, GxpS was chosen for the generation of a focused peptide library created via a one-shot yeast based TAR cloning approach (Schimming et al. 2014, Gietz et al. 2007). Here, the third position of the peptide (D-Phe) was randomized (FIG. 5) using six unique XU.sub.2.0 building blocks from six NRPS (KolS (Bode et al. 2015), AmbS.sub.mir (Schimming et al. 2014), Pax (Fuchs et al. 2011), AmbS.sub.ind, XllS; for detail see FIG. 8), resulting in the production of 1 and four new GameXPeptide derivatives (22-25) in yields of 3-92 mg/L that were structurally confirmed by chemical synthesis.

[0108] For the generation of a second and structurally more diverse library, positions 1 (D-Val) and 3 (D-Phe) of GxpS were selected in parallel for randomization (FIG. 6). From the experimental setup theoretically 48 different cyclic and linear peptides could have been expected. Screening of 50 E. coli clones resulted in the identification of 18 unique cyclic and linear peptides (1, 4, 11, 13, 24, 26-36) differing in length and AA composition. Since only 7 out of 18 identified peptides belong to the expected set of peptides, homologues recombination in yeast based reprogramming of NRPS also allows the production of unexpected peptides due to unexpected homologues recombination events resulting in an additional layer of peptide diversification, as recorded in previous experiments (WO 2017/020983).

[0109] Randomizing adjacent positions via a one shot yeast based TAR cloning approach assumes a standardized nucleotide sequence (40-80 base pairs) for homologues recombination. (Schimming et al. 2014, Gietz et al. 2007). By exploring the T-C didomain crystal structure of TycC5-6 (PDB-ID: 2JGP), the helix .alpha.5 (I253-F265) next to the C-domain's pseudo-dimer linker was identified as an ideal target for homologues recombination. Following, an artificial .alpha.5 helix was designed to randomize position 2 (L-Leu) and 3 (D-Phe) of GxpS, being an integral part of all resulting recombinant C3 domains--connecting XU.sub.2.02 and 3. The applied as helix was defined as the consensus sequence of all involved XU.sub.2.0 building blocks (FIG. 7a). Screening of 25 E. coli clones revealed the synthesis of 7 cyclic and linear GameXPeptides (1, 23, 38-42), showing the general applicability of redesigning .alpha.5 with respect to randomly reprogramming biosynthetic templates (FIG. 7b).

[0110] Very recently the concept of XU was published, enabling the guided reprogramming of NRPS for the first time (WO 2017/020983). Nevertheless, the inventors attempted to develop a more user-friendly and straightforward way to achieve the de novo design of NRPS from scratch. The novel XU.sub.2.0 building block presented here brings crucial advantages compared with all other up to now published strategies (Win et al. 2015, Calcott & Ackerley 2014). In comparison to the state-of-the-art XU concept, the XU.sub.2.0 enables reprogramming of NRPSs by solely altering one unit since the XU.sub.2.0 automatically modulates C-domain specificities. Moreover, much less building blocks are required to introduce any changes into the appropriate biosynthetic template. For example, to create any peptide based on the 20 proteinogenic AAs only 80 XU.sub.2.0 building blocks are necessary--only four of each: C.sub.Dsub-A-T-C.sub.Asub, C.sub.Dsub-A-T-C/E.sub.Asub, C/E.sub.Dsub-A-T-C/E.sub.Asub, and C/E.sub.Dsub-A-T-C.sub.Asub. In contrast, 800 XU building blocks would be necessary to generate the same spectrum of peptides. Consequently, the introduction of the XU.sub.2.0 enormously simplifies and broadens the possibilities of biotechnological applications with regard to optimize bioactive agents via NRPS engineering.

[0111] In summary the inventors demonstrated how C-domain specificities can be avoided (FIG. 1) and how this knowledge can be applied to flexibly reprogram NRPSs and to functionalize NRPs by incorporating XU.sub.2.0 building blocks accepting non-natural AAs like p-N.sub.3-Phe and Y-Tyr (FIG. 4,). As azides and alkynes readily undergo bioorthogonal click reactions, p-N.sub.3-Phe and Y-Tyr incorporating NRPs can be used for further derivatization (Sletten & Bertozzi 2009, Kolb & Sharpless 2003). Consequently, NRPSs able to incorporate clickable AAs into the produced peptides provide a powerful means of isolating, labelling, and modifying biologically active peptides (Kries et al. 2015).

[0112] The true strength of the XU.sub.2.0's flexibility, however, lay in the ability to generate random NP-like peptide libraries for subsequent bioactivity screenings. The simple randomization of two building blocks from GxpS and subsequent screening of only 50 E. coli clones led to the identification of 19 novel peptides. The possible automation of screening in line with assays for bioactivity, e.g. via intelligent droplet based microfluidics, opens up entirely new opportunities of identifying novel lead compounds in the future. Especially in the area of anti-infective research underlying results might be an issue very important in practice, namely to fight upcoming antimicrobial resistances.

Materials and Methods

Cultivation of Strains

[0113] All E. coli, Photorhabdus and Xenorhabdus strains were grown in liquid or solid LB-medium (pH 7.5, 10 g/L tryptone, 5 g/L yeast extract and 5 g/L NaCl). Solid media contained 1.5% (w/v) agar. S. cerevisiae strain CEN.PK 2-1C and derivatives were grown in liquid and solid YPD-medium (10 g/L yeast extract, 20 g/L peptone and 20 g/L glucose). Agar plates contained 1.5% (w/v) agar. Kanamycin (50 .mu.g/ml) and G418 (200 .mu.g/ml) were used as selection markers. E. coli was cultivated at 37.degree. C. all other strains were cultivated at 30.degree. C.

Expression and Cultivation of His-Tagged Proteins

[0114] For overproduction and purification of the .about.72 Da His-tagged A domain GxpS_A3 5 ml of an overnight culture in LB medium of E. coli BL21 (DE3) cells harboring the corresponding expression plasmid and the TaKaRa chaperone-plasmid pTf16 (TAKARA BIO INC.) were used to inoculate 500 ml of autoinduction medium (464 ml LB medium, 500 .mu.l 1 M MgSo.sub.4, 10 ml 50.times.5052, 25 ml 20.times.NPS) containing 20 .mu.g/mL chloramphenicol, 50 .mu.g/mL kanamycin and 0.5 mg/ml L-arabinose (Nishihara et al. 2000). The cells were grown at 37.degree. C. up to an OD.sub.600 of 0.6. Following the cultures were cultivated for additional 48 h at 18.degree. C. The cells were pelleted (10 min, 4,000 rpm, 4.degree. C.) and stored overnight at -20.degree. C. For protein purification the cells were reuspended in binding buffer (500 mM NaCl, 20 mM imidazol, 50 mM HEPES, 10% (w/v) glycerol, pH 8.0). For cell lysis benzonase (Fermentas, 500 U), protease inhibitor (Complete EDTA-free, Roche), 0.1% Triton-X and lysozym (0.5 mg/ml, .about.20,000 U/mg, Roth) were added and the cells were incubated rotating for 30 min. After this the cells were placed on ice and lysed by sonication. Subsequently, the lysed cells were centrifuged (25,000 rpm, 45 min, 4.degree. C.). The yielded supernatant was passed through a 0.2 .mu.m filter and loaded with a flow rate of 0.5 ml/min on a 1 ml HisTrap.TM. HP column (GE Healthcare) equilibrated with binding buffer. Unbound protein was washed off with 10 ml binding buffer. Impurities were washed off with 5 ml 8% elution buffer (500 mM NaCl, 500 mM imidazol, 50 mM HEPES, 10% (w/v) glycerol, pH 8.0). The purified protein of interest was eluted with 39% elution buffer. Following, the purified protein containing fraction was concentrated (Centriprep.RTM. Centrifugal Filters Ultacel.RTM.YM--50, Merck Millipore) and the buffer was exchanged to 20 mM Tris-HCl (pH 7.5) using a PD-10 column (Sephadex.TM. G-25 M, GE Healthcare).

Cloning of GxpS_A3

[0115] The adenylation domain GxpS_A3 was cloned from Photorhabdus luminescens TTO1 genomic nomic DNA by PCR using the pCOLA_Gib_A3 Insert forward and reverse oligonucleotides shown in Tab. 1. The plasmid backbone of pCOLADUET.TM.-1 (Merck/Millipore) was amplified using the DUET_Gib forward and reverse oligonucleotides shown in Tab 1. The .about.1,900 bp PCR product was cloned via Gibson Assembly.RTM. Cloning Kit (NEB) according to the manufacturers' instructions into pCOLADUET.TM.-1.

.gamma.-.sup.18O.sub.4-ATP Pyrophosphat Exchange Assay

[0116] The .gamma.-.sup.18O.sub.3-ATP Pyrophosphat Exchange Assay was performed as published previously (Kronenwerth et al. 2014, Phelan et al. 2009). After an incubation period of 90 min at 24.degree. C. the reactions were stopped by the addition of 6 .mu.l 9-aminoacridine in acetone (10 mg/ml) for MALDI-Orbitrap-MS analysis.

MALDI-Orbitrap-MS

[0117] Samples were prepared for MALDI-analysis as a 1:1 dilution in 9-aminoacridine in acetone (10 mg/ml) and spotted onto a polished stainless steel target and air-dried. MALDI-Orbitrap-MS analyses were performed with a MALDI LTQ Orbitrap XL (Thermo Fisher Scientific, Inc., Waltham, Mass.) equipped with a nitrogen laser at 337 nm. The following instrument parameters were used: laser energy, 27 .mu.J; automatic gain control, on; auto spectrum filter, off; resolution, 30,000; plate motion, survey CPS. Mass spectra were obtained in negative ion mode over a range of 500 to 540 m/z. The mass spectra for ATP-PP.sub.i exchange analysis were acquired by averaging 50 consecutive laser shots. Spectral analysis was conducted using Qual Browser (version 2.0.7; Thermo Fisher Scientific, Inc., Waltham, Mass.).

Cloning of Biosynthetic Gene Clusters

[0118] Genomic DNA of selected Xenorhabdus and Photorhabdus strains were isolated using the Qiagen Gentra Puregene Yeast/Bact Kit. Polymerase chain reaction (PCR) was performed with oligonucleotides obtained from Eurofins Genomics (Tab. 1). Fragments with homology arms (40-80 bp) were amplified in a two-step PCR program For PCR Phusion High-Fidelity DNA polymerase (Thermo Scientific), Q5 High-Fidelity DNA polymerase (New England BioLabs) and Velocity DNA polymerase (Bioline) were used. Polymerases were used according to the manufacturers' instructions. DNA purification was performed from 1% TAE agarose gel using Invisorb.RTM. Spin DNA Extraction Kit (STRATEC Biomedical AG). Plasmid isolation from E. coli was done by alkaline lysis.

Overlap Extnesion PCR-Yeast Homologous Recombination (ExRec)

[0119] Transformation of yeast cells was done according to the protocols from Gietz and Schiestl (Gietz et al. 2007). 100-2,000 ng of each fragment was used for transformation. Constructed plasmids were isolated from yeast transformants and transformed in E. coli DH10B::mtaA by electroporation. Successfully transformed plasmids were isolated from E. coli transformants and verified by restriction digest.

Heterologous Expression of NRPS Templates and LC-MS Analysis

[0120] Constructed plasmids were transformed into E. coli DH10B::mtaA. Strains were grown overnight in LB medium containing 50 .mu.g/mL kanamycin. 100 .mu.l of an overnight culture were used for inoculation of 10 ml cultures, containing 0.02 mg/ml L-arabinose and 2% (v/v) XAD-16. 50 .mu.g/mL kanamycin were used as selection markers. After incubation for 72 h at 22.degree. C., respectively, the XAD-16 was harvested. One culture volume methanol was added and incubated for 30 min. The organic phase was filtrated and evaporated to dryness under reduced pressure. The extract was diluted in 1 mL methanol and a 1:10 dilution was used for LC-MS analysis as described previously (Fuchs et al. 2013 & 2014). All measurements were carried out by using an Ultimate 3000 LC system (Dionex) coupled to an AmaZonX (Bruker) electron spray ionization mass spectrometer. High-resolution mass spectra were obtained on a Dionex Ultimate 3000 RSLC Coupled to a Bruker micro-TOF-Q II equipped with an ESI Source set to positive ionization mode. The software DataAnalysis 4.3 (Bruker) was used to evaluate the measurements.

Homology-Modelling

[0121] The homology-modelling was performed as described previously {Fuchs:2013cv}. For homology modelling, the 1.85 .ANG. crystal structure of PCP-C bidomain TycC 5-6 from tyrocidine syntethase (TycC) of Brevibacillus brevis (PDB-ID: 2JGP) were used {Samel:2007eh}. The sequence identity of GxpS_C3 in comparison to TycC 5-6 is 34.8%, respectively. The final models have a root-mean-square deviation (RMSD) of 1.4 .ANG. respectively, in comparison to the template structures.

10. Peptide Quantification

[0122] All peptides were quantified using a calibration curve of synthetic 1 (for quantification of 1-4), 5 (for quantification of 5, 34, 35, 37, 38 and 39), 9 (for quantification of 9, 14 and 15), 10 (for quantification of 10, 11, 12, 13, 26, 27, 28, 29, 30, 31 and 36), 17 (for quantification of 16 and 17), 18, 19 (for quantification of 19, 20 and 21), 22, 23, 24 (for quantification of 24 and 39), 25 (for quantification of 25 and 33), and cyclo[RLflL] (for quantification of 32 and 40) using HPLC/MS measurements as described above. Triplicates of all experiments were measured.

TABLE-US-00001 TABLE 1 Oligonucleotides used in this work. Oligo- Plas- nucleo- SEQ mid tide Sequence (5'.fwdarw.3') Template ID pCO- pCOLA CATCACCATCATCACCACCCTCAACAACCTGTCACGGC P. 1 LA_gx _Gib_A lumine pS_A3 3 Insert ne- FW scens TT01 pCOLA CAGCCTAGGTTAATTAAGCTGTTAAGTCAGATCAATCAGCGGCAAC 2 _Gib_A 3 Insert RV DUET_ CAGCTTAATTAACCTAGGCTG pCO- 3 Gib_F LADU W ET-1 DUET_ GTGGTGATGATGGTGATG 4 Gib_RV pFF1 KB-RT- TCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCG P. 5 NRPS_ 6 CCTCCGCTTCACAATTC lumine 1 ne- scens TT01 KB-RT- TGGAATGCGACCGAAGAACC 6 7 KB-RT- CACATACCTGAGTAGGATACGGTTCTTCGGTCGCATTCCAAGTTTTC X. 7 8 AGCAACAACTGGC buda- pes- tensis DSM 16342 KB-RT- TGTTTTGCCTGCATCGGAACGCACGTTGTTGCTGGAAACGTGGAAT 8 9 ACAACGGAAACTGC KB-RT- CGTTTCCAGCAACAACG P. 9 10 lumine ne- scens TT01 KB-RT- TTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCATGAAAG 10 11 ATAGCATGGCTAAAAAGG pFF1_ KB-RT- TCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCG P. 11 NRPS_ 6 CCTCCGCTTCACAATTC lumine 2 ne- scens TT01 KB-RT- TGGAATGCGACCGAAGAACC 12 7 KB-RT- AAGCCATTGACGCTGCCAG X. 13 15 buda- pes- tensis DSM 16342 KB-RT- TGTTTTGCCTGCATCGGAACGCACGTTGTTGCTGGAAACGTGGAAT 14 9 ACAACGGAAACTGC KB-RT- CGTTTCCAGCAACAACG P. 15 10 lumine ne- scens TT01 KB-RT- TTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCATGAAAG 16 11 ATAGCATGGCTAAAAAGG KB-RT- CACATACCTGAGTAGGATACGGTTCTTCGGTCGCATTCCAATTTTCC P. 17 13 AGTAATAACTCCCGCTC lumine ne- scens TT01 KB-RT- TCAATATCCTGATTATGCGGTCTGGCAGCGTCAATGGCTTTCAGGTG 18 14 AAGGAGTACAGGC pFF1 AL- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT X. 19 NRPS GxpS- GAAAGATAGCATGGCTAAAAAGG nema- 3 2-1 tophila ATCC 19061 AL- CCCAATCAACATATCGGTAAAAAAGCGAGTATGTTCCATCTGGCTCA 20 GxpS- CCCCCTGGTGGGCC 2-2 AL- CCCGTACCTTTCCGTAATCTGGTCGCTCAGGCCCACCAGGGGGTGA X. 21 GxpS- GCCAGATGGAACATACTCG mira- 2-3 niensis DSM 17902 AL- CGTCCGACGCCAATAATCACTCTGTGCCTGTACTCCTTCACCTGAAA 22 GxpS- ACCACTGGCGTTGCC 2-4 AL- TCAGGTGAAGGAGTACAGGCAC P. 23 GxpS- lumine 2-5 ne- scens TT01 AL- GACACCCTGCCGAGCC 24 GxpS- 2-6 AL- CCGGTCCCGTTCCGCCATTTAGTGGCACAGGCTCGGCAGGGTGTC X. 25 GxpS- CAAGGCGCTGTTCTCACTG bovi- 2-7 enii SS200 4 AL- CTCAGCCAACATTTCAGTAAAGAAACGGGTATGTTCAGCCTGACTCA 26 GxpS- CGCTCAGGGTCTGGG 2-8 AL- AGTCAGGCTGAACATACCCG P- 27 GxpS- lumine 2-9 ne- scens TT01 AL- TTTGCTCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCC 28 GXpS- AGCGCCTCCGCTTCAC 2-10 pFF1_ AL- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT X. 29 NRPS_ GxpS- GAAAGATAGCATGGCTAAAAAGG nema- 4 2-1 tophila ATCC 19061 AL- CCCAATCAACATATCGGTAAAAAAGCGAGTATGTTCCATCTGGCTCA 30 GXpS- CCCCCTGGTGGGCC 2-2 AL- CCCGTACCTTTCCGTAATCTGGTCGCTCAGGCCCACCAGGGGGTGA X. 31 GXpS- GCCAGATGGAACATACTCG mira- 2-3 niensis DSM 17902 AL- CGTCCGACGCCAATAATCACTCTGTGCCTGTACTCCTTCACCTGAAA 32 GXpS- ACCACTGGCGTTGCC 2-4 AL- TCAGGTGAAGGAGTACAGGCAC P. 33 GxpS- lumine 2-5 ne- scens TT01 AL- GACACCCTGCCGAGCC 34 GxpS- 2-6 AL- GCCGGTCCCGTTCCGCCATTTAGTGGCACAGGCTCGGCAGGGTGT X. 35 GxpS- CAGTCAGGAAGCCCACACC mira- 2-11 niensis DSM 17902 AL- CTCAGCCAACATTTCAGTAAAGAAACGGGTATGTTCAGCCTGACTCA 36 GXpS- CCCCCAACCGAACC 2-12 AL- AGTCAGGCTGAACATACCCG P. 37 GxpS- lumine 2-9 ne- scens TT01 AL- TTTGCTCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCC 38 GXpS- AGCGCCTCCGCTTCAC 2-10 pFF1_ ML020 AGATTAGCGGATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGT pFF1_ 39 NRPS_ TTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCATGAAAG NRPS 5 ATAACATTGCTACAGTG _0 FF_305 CCAATAATCACTCTGTGCCTG 40 FF_306 GAACTGGTTGCACTTTACGC 41 FF_307 CATCCCTAACCGGGACTG 42 FF_308 CATACCTTGACGGACAGGGCGGCAACCTGCCAGCGCCGGCACCCT X. 43 TCCGCAATCTGGTAGCGCAGTCCCGGTTAGGGATGAGTCAGGCAG buda- CCCATACC Pes- tensis DSM 16342 FF_309 AACAACACCGGTAAACAGTTCTTCACCTTTGCTCATGAACTCGCCAG 44 AACCAGCAGCGGAGCCAGCGGATCCGGCGCGCCCTATTGCTCTGC TGATATCAGAA pFF1_ ML_P1 GACCAGACAGAACATCACCG pFF1_ 45 NRPS_ gxpS_ 6 WT ML_P2 GGCCCAATCCTATACGCC 46 ML_P3 CTTACCAAGCGCCACAAGG 47 ML_P4 AGAATCGGAACAACACCGGTAAACAGTTCTTCACCTTTGCTCATGAA 48 CTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCGCCTCCGC TTCA ML_P5 TCGGTCAGCCCAAACGGTAATGTCGGTTCATCCACTTCTGCCAACAT X. 49 GTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCGACACCCTGCCGA nema- GCC tophila HGB0 81 ML_P6. ATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATACC 50 1 CGTTTTTTTGGGCTAACAGGAGGAATTCCATGCGGGCAATGGTGAA CC pFF1_ ML_Pl GACCAGACAGAACATCACCG pFF1_ 51 NRPS_ gxpS_ 7 WT ML_P2 GGCCCAATCCTATACGCC 52 ML_P3 CTTACCAAGCGCCACAAGG 53 ML_P4 AGAATCGGAACAACACCGGTAAACAGTTCTTCACCTTTGCTCATGAA 54 CTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCGCCTCCGC TTCA ML_P5 TCGGTCAGCCCAAACGGTAATGTCGGTTCATCCACTTCTGCCAACAT X. 55 GTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCGACACCCTGCCGA nema- GCC tophila HGB0 81

ML_P6. ATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATACC 56 3 CGTTTTTTTGGGCTAACAGGAGGAATTCCATGTCTGATGAAGGCGT GC pFF1 ML_P1 GACCAGACAGAACATCACCG pFF1_ 57 NRPS_ gxpS_ 8 WT ML_P2 GGCCCAATCCTATACGCC 58 ML_P3 CTTACCAAGCGCCACAAGG 59 ML_P4 AGAATCGGAACAACACCGGTAAACAGTTCTTCACCTTTGCTCATGAA 60 CTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCGCCTCCGC TTCA ML_P5 TCGGTCAGCCCAAACGGTAATGTCGGTTCATCCACTTCTGCCAACAT X. 61 GTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCGACACCCTGCCGA nema- GCC tophila HGB0 81 ML_P6. ATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCATACC 62 2 CGTTTTTTTGGGCTAACAGGAGGAATTCCATGGCATTTACCGAAAAG ATCTGCG pFF1_ ML_P7 CGGATCCTACCTGACGCTTTTTATCGCAACTCTCTACTGTTTCTCCA X. 63 NRPS_ TACCCGTTTTTTTGGGCTAACAGGAGGAATTCCATGAAAGATAGCAT nema- 9 GGCTAAAAAGGG tophila HGB0 81 ML_P8 CTATCGGCAATTCAAGTAACACCGGTGCATCTGCCAACGTCCGACG 64 CCAATAATCACTCTGTGCCTGTACTCCTTCACCTGAAAATACCTGCC GCTGCC ML_P9 GCTTGTCTGAATCAACAACCTGATCCGCTGCCGCCATTGACCATTCA 65 ATATCCTGATTATGCTGCCTGGCAGCGGCAGGTATTTTCAGGTGAA GGAGTACAGGC ML_P1 GCACTTCCGACAATCCAAATGACAACGTTGGCTCATCTACCTCAGCC 66 0 AACATATCGGTAAAGAAACGGGTATGTTCTGCCTGACTGACACCCT GCCGAGCC ML_P1 GGCTTGCCTCTTGGGGCAAATGGATAGCCTGCCTGCGCCGGTCCC X. 67 1 GTTCCGCCATTTAGTGGCACAGGCTCGGCAGGGTGTCAGTCAGGC nema- AGAACATACCCG tophila HGB0 81 ML_P1 CCAGAATCGGAACAACACCGGTAAACAGTTCTTCACCTTTGCTCATG 68 2 AACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCGCCTCC ACTTCG pFF1_li KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 69 bra- AmbF-1 GGTTGAACGCTTACAATCC mira- ry_1 niensis DSM 17902 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTG 70 AmbF-2 ATACCCAGCCGGGCTTG KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 71 AmbW- ATCGGAACGGGTACAAATTC indica 1 DSM 17382 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTTA 72 AmbW- CCCCCATCCGTGCCTG 2 KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC P. 73 Thr1 GGCAGCACAGATACAGTCTC lumine ne- scens TT01 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCA 74 Thr2 CGCCCAACCGGACC KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 75 Arg1 TGCTGATCGTATTCAGGTGCAG buda- pes- tensis DSM 16342 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCA 76 Arg2 CGCCCAACCGGACC KB- GTCTAAATCAACAGCCAGATCCGTTGTTGCCATTGACCATTCAATAT X. 77 Ser1 CCTGATTATGCGGCTTGGCAGCGGCAGGTATTTCAGGGTGACCGCC sze- TGAC ntirmai i DSM 16338 KB- TCCGCCAACCCAAATAGCAGCGTCGGTTCATCCACCTCAGCCAACA 78 Ser2 TGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCACACTCAGGATT TGAGCGATAAAG KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTCA X. 79 Lys1 GGGTGAGGTACTGGAAAAGC nema- tophila HGB0 81 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTTA 80 Lys2 CACTGCGGGTTTGGGC AL- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT pFF1_ 81 GxpS-1 GAAAGATAGCATGGCTAAAAAGG gxpS_ WT AL- AAATACCTGCCGCTGCC 82 GxpS-2 AL- AGTCAGGCAGAACATACTCGCTTCTTTAC 83 GxpS-3 AL- TTTGCTCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCC 84 GxpS-4 AGCGCCTCCGCTTCAC pFF1 _li KB- TTCTGCCAACATGTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCTT X. 85 bra- xeyS-C CCCCCAACCAGGACTG indica ry 2 DSM 17382 KB- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT 86 xeyS-N GAAAGATAACATGGCTACAACG KB- TTCTGCCAACATGTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCCA X. 87 BicA-C TCCCCAACCAGGACTG buda- pes- tensis DSM 16342 KB- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT 88 BicA-N GAAAGATAACATTGCTACAGTGG KB- TTCTGCCAACATGTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCAA X. 89 17902- CGCCCAGCCGGGCTTGAGC mira- C niensis DSM 17902 KB- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT 90 17902- GAAAAATGATAAGGTGATGACTCTGC N KB- TTCTGCCAACATGTCGGTAAAGAATCGGTGATGTTCTGTCTGGTCCA X. 91 2022-C CCCCCTGGTGGGCC nema- tophila HGB0 81 KB- ACTGTTTCTCCATACCCGTTTTTTTGGGCTAACAGGAGGAATTCCAT 92 2022-N GAAAGATAGCATGGCTAAAAAGG KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTCA X. 93 XLSer1 GGGTGACCGCCTGAC sze- ntirmai i DSM 16338 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCA 94 XLSer2 CACTCAGGATTTGAGCGATAAAG KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 95 AmbF-1 GGTTGAACGCTTACAATCC mira- niensis DSM 17902 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTG 96 AmbF-2 ATACCCAGCCGGGCTTG KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 97 AmbW- indica 1 ATCGGAACGGGTACAAATTC DSM 17382 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTTA 98 AmbW- CCCCCATCCGTGCCTG 2 KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC P. 99 Thr1 GGCAGCACAGATACAGTCTC lumine ne- scens TT01 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCA 100 Th 2 CGCCCAACCGGACC KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTC X. 101 Arg1 TGCTGATCGTATTCAGGTGCAG buda- pes- tensis DSM 16342 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCA 102 Arg2 CGCCCAACCGGACC KB- ACCATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTCA X. 103 Lys1 GGGTGAGGTACTGGAAAAGC nema- tophila HGB0 81 KB- CTCAGCCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTTA 104 Lys2 CACTGCGGGTTTGGGC AL- AGTCAGGCAGAACATACTCGCTTCTTTAC pFF1_ 105 GxpS gxpS_ P3 WT AL- TTTGCTCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCC 106 GxpS- AGCGCCTCCGCTTCAC P4 KB- GACCAGACAGAACATCACCG 107 Lib3-1 KB- AAATACCTGCCGCTGCC 108 Lib3-2 pFF1_li KB-XL- CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCACACTC X. 109 bra- X3 RV AGGATTTGAGCG sze- ry 3 ntirmai i DSM 16338 KB-XL- ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTCAGG 110 X3 FW GTGACCGCCTGACC KB-XI- CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCATACCT X. 111 amb X3 AGACGTGCCTGTGC indica RV DSM 17382 KB-XI- ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTCGGC 112 amb X3 AGAACGGATACAAATTC FW KB-Kol CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCACGCC P. 113 X3 - RV CAACCGGACC lumine ne-

scens TT01 KB-Kol ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTCGGC 114 X3 - AGCACAGATACAGTC FW KB-Kol AAATACCTGCCGCTGCCAAGCCGCATAATCAGGATATTGAATCGTCA P. 115 X2 RV ACGGTAGCAACGG lumine ne- scens TT01 KB-Kol ACCTTTCCGCAATCTGGTGGCTCAGGCTCGGCAGGGGGTTAGTCAG 116 X2 FW GCTGAGCATACCCG KB- CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTCACGCC X. 117 BicA X3 CAACCGGACC buda- RV pes- tensis DSM 16342 KB- ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTCTGC 118 BicA X3 TGATCGTATTCAGGTGC FW KB-Bb TCATGAACTCGCCAGAACCAGCAGCGGAGCCAGCGGATCCCAGCG pFF1_ 119 2 RV CCTCCGCTTCACAATTC gxpS_ WT KB-Bb AGTCAGGCAGAACATACTCGC 120 2 FW KB-Bb AACCCCCTGCCGAGCC pFF1_ 121 1 RV gxpS_ WT KB-Bb AACCCCCTGCCGAGCC 122 1 FW KB- AAATACCTGCCGCTGCCAAGCCGCATAATCAGGATATTGAATTGCCA X. 123 amb X2 ATGGTGGCAAGGG indica RV DSM 17382 KB- ACCTTTCCGCAATCTGGTGGCTCAGGCTCGGCAGGGGGTTAGCCA 124 amb X2 GACAGAGCACACCCG FW KB- CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTGATACCC X. 125 17902 AGCCGGGCTTGTGC mira- X3 RV niensis DSM 17902 KB- ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTCGGT 126 17902 TGAACGCTTACAATCC X3 FW KB- CCAACATGTCAGTAAAGAAGCGAGTATGTTCTGCCTGACTGACACC X. 127 2022 CTGCCGAGCC nema- X3 RV tophila HGB0 81 KB- ATTCAATATCCTGATTATGCGGCTTGGCAGCGGCAGGTATTTTCTGA 128 2022 TGAAGGCGTGCAGG X3 FW KB- AAATACCTGCCGCTGCCAAGCCGCATAATCAGGATATTGAATGGTC X. 129 2022 AATGGCGGCAGCGG nema- X2 RV tophila HGB0 81 KB- ACCTTTCCGCAATCTGGTGGCTCAGGCTCGGCAGGGGGTTAGTCAG 130 2022 GAAGCGTACACGCG X2 FW

LITERATURE

[0123] Altschul S F, Gish W, Miller W, Myers E W, Lipman D J, J. Mol. Biol. 1990, 215, 403-410

[0124] Belshaw P J, Walsh C T, Stachelhaus T, Science 1999, 284, 486-9-489

[0125] Bloudoff, K, Rodionov, D & Schmeing, T M. J. Mol. Biol. 2013, 425, 3137-3150.

[0126] Bode H B, Reimer D, Fuchs S W, Kirchner F, Dauth C, Kegler C, Lorenzen W, Brachmann A O, Grun P. Chemistry--A European Journal 2012, 18, 2342.

[0127] Bode H B, Brachmann A O, Jadhav K B, Seyfarth L, Dauth C, Fuchs S W, Kaiser M, Waterfield N R, Sack H, Heinemann S H, Arndt H D. Angew Chem Int Ed Engl 2015, 54, 10352.

[0128] Bozhueyuek K A J, Fleischhacker F, Linck A, Tietze A, Niesert C P, Bode H B. Nat Chem. 2017, doi:10.1038/nchem.2890

[0129] Bruner S D, Weber T, Kohli R M, Schwarzer D, Marahiel M A, Walsh C T, Stubbs M T. Structure 2002, 10, 301-310.

[0130] Cai X, Nowak S, Wesche F, Bischoff I, Kaiser M, Furst R, Bode H B. Nat Chem. 2017, 9, 379-386.

[0131] Calcott, M J & Ackerley D F. Biotechnol Lett 2014, 36, 2407-16.

[0132] Cane D E, Walsh C T, Khosla C, Science 1989, 282, 63-68.

[0133] Clugston S L, Sieber S A, Marahiel M A, Walsh C T. Biochemistry 2003, 42, 12095-104.

[0134] Conti E, Stachelhaus T, Marahiel M A, Brick P. EMBO J. 997, 16, 4174-83.

[0135] Cosmina, P., Rodriguez, F., Ferra, F., Grandi, G., Perego, M., Venema, G., & Sinderen, D. Mol Microbiol 1993, 8, 821-831.

[0136] De Crecy-Lagard V, Marliere P, Saurin W. C R Acad Sci III. 1995, 318, 927-36.

[0137] Du L & Lou L. Nat. Prod. Rep. 2009, 27, 255-78.

[0138] Emmel E A, Verweij C L, Durand D B, Higgins K M, Science 1989, 246, 1617-1620.

[0139] Fuchs S W, Proschak A, Jaskolla T W., Karas M & Bode H B. Org Biomol Chem 2011, 9, 3130-3132.

[0140] Fuchs S W, Sachs C C, Kegler C, Nollmann F I, Karas M, Bode H B. Analytical Chemistry 2012, 84, 6948.

[0141] Fuchs S W, Bozhuyuk K A, Kresovic D, Grundmann F, Dill V, Brachmann A O, Waterfield N R, Bode H B. Angewandte Chemie (International ed. in English) 2013, 52, 4108-4112.

[0142] Gao, X. Haynes S W, Ames B D, Wang P, Vien L P, Walsh C T, Tang Y. Nat. Chem. Biol. 2012, 8, 823-830 (2012).

[0143] Gaudelli N M & Townsend C A. Nat. Chem. Biol. 2014, 10, 251-258.

[0144] Gietz R D & Schiestl R H. Nat Protoc 2007, 2, 1-4.

[0145] Harvey A L, Edrada-Ebel R & Quinn R J. Nat Rev Drug Discov 2015, 14, 111-29.

[0146] Haynes S W Ames BD, Gao X, Tang Y, Walsh C T. Biochemistry 2011, 50, 5668-5679.

[0147] Horsman M E, Hari T P A. & Boddy C N. Nat. Prod. Rep. 2015. doi:10.1039/c4np00148f

[0148] Ishizuka M, Takayama H, Takeuchi T, J. Antibiot. 1967, 20, 15-24.

[0149] Keating T A, Marshall C G, Walsh C T, Keating A E, Nat Struct Biol. 2002, 9, 522-6.

[0150] Kegler C, Nollmann F I, Ahrendt T, Fleischhacker F, Bode E, Bode H B. ChemBioChem 2014, 15, 826.

[0151] Kohli R M, Trauger J W, Schwarzer D, Marahiel M A, Walsh C T. Biochemistry, 2001, 40, 7099-7108.

[0152] Kolb H C, Sharpless K B. Drug Discov Today. 2003, 8, 1128-37.

[0153] Konz, D., Klens, A., Schorgendorfer, K. & Marahiel, M. A. Chem Biol 1998, 4, 927-937.

[0154] Kopp F & Marahiel M A. Nat. Prod. Rrep. 2007, 24, 735-49.

[0155] Korman T P, Crawford J M, Labonte J W, Newman A G, Wong J, Townsend C A, Tsai S C. Proc. Natl. Acad. Sci. USA 2010, 107, 6246-6251.

[0156] Kries H, Wachtel R, Pabst A, Wanner B, Niquille D, Hilvert D, Angew. Chem. Int. Ed. 2014, 53, 10105-10108.

[0157] Kronenwerth M, Bozhuyuk K A, Kahnt A S, Steinhilber D, Gaudriault S, Kaiser M, Bode H B. Chemistry--A European Journal 2014, 20, 17478-87.

[0158] Lefevre F, Robe P, Jarrin C, Ginolhac A, Zago C, Auriol D, Vogel T M, Simonet P, Nalin R. Res Microbiol 2008, 159, 153-61.

[0159] Ling L L, Schneider T, Peoples A J, Spoering A L. Nature 2015, 517, 445-459.

[0160] Loeffler W, Tschen J, Vanittanakom N. J. Phytopathol. 1986, 115, 204-213.

[0161] Marahiel M A, Chem. Biol. 997, 4, 561-567.

[0162] Marahiel M A. Nat Prod Rep 2015. doi:10.1039/c5np00082c

[0163] Meyer S, Kehr J C, Mainz A, Dehm D, Petras D, Sussmuth R D, Dittmann E. Cell Chem Biol 2016, 23, 462-471.

[0164] Mitchell C A, Shi C, Aldrich CC, Gulick A M. Biochemistry 2012, 51, 3252-3263.

[0165] Nishihara K, Kanemori M, Yanagi H & Yura, T. Applied and environmental microbiology 2000, 66, 884-889.

[0166] Nollmann F I, Dauth C, Mulley G, Kegler C, Kaiser M, Waterfield N R, Bode H B. ChemBioChem 2014, 16, 205-8.

[0167] Li R, Oliver R A. & Townsend C A. Cell Chem Biol 2016, 24, 24-34.

[0168] Phelan V V, Du Y, McLean J A, Bachmann B O. Chem Biol. 2009, 29, 16, 473-8.

[0169] Rausch C, Weber T, Kohlbacher O, Wohlleben W, Huson D H. Nuc. Acids. Res. 2005, 33, 5799-5808.

[0170] Rausch C, Hoof I, Weber T, Wohlleben W, Huson D H. BMC Evol Biol. 2007, 7:78.

[0171] Reimer D, Cowles K N, Proschak A, Nollmann F I, Dowling A J, Kaiser M, ffrench-Constant R, Goodrich-Blair H, Bode H B. ChemBioChem 2013, 14, 1991-997.

[0172] Samel S A, Schoenafinger G, Knappe T A, Marahiel M A & Essen L O. Structure 2007, 15, 781-792.

[0173] Schimming O, Fleischhacker F, Nollmann F I & Bode H B. ChemBioChem 2014, 15, 1290.

[0174] Sieber S A, Marahiel M A. Chem. Rev. 2005, 105, 715-738.

[0175] Sletten E M, Bertozzi C R. Angew Chem Int Ed Engl. 2009, 48, 6974-98.

[0176] Smith S, Tsai S. Nat. Prod. Rep. 2007, 24, 1041-1072.

[0177] Stachelhaus T, Schneider A, Marahiel M A. Science 1995, 269, 69-72.

[0178] Stachelhaus T, Mootz H D, Bergendahl V, Marahiel M A. J Biol Chem. 1998, 273, 22773-81.

[0179] Stachelhaus T, Mootz H D, Marahiel M A. Chem. Biol. 1999, 6, 493-505.

[0180] Strieker M & Marahiel M A. Curr. Opin. Struct. Biol. 2010, 10, 234-240.

[0181] Sundlov J A & Gulick A M. Acta Crystallogr. D. Biol. Crystallogr 2013, 69, 1482-1492.

[0182] Sussmuth R D, Mainz A. Angew Chem Int Ed Engl. 2017, 56, 3770-3821.

[0183] Tan X F, Dai Y N, Zhou K, Jiang Y L, Ren Y M, Chen Y, Zhou C Z. Acta Cryst 2015, D71, 873-881.

[0184] Tanovic A, Samel S A, Essen L O, Marahiel M A. Science 2008, 321, 659-663

[0185] Trauger J W, Kohli R M, Walsh C T. Nature 2000, 407, 215-218.

[0186] Tseng C C, Bruner S D, Kohli R M, Marahiel M A, Walsh C T, Sieber S A. Biochemistry 2002, 41, 13350-13359.

[0187] Winn, M, Fyans, J K, Zhuo Y & Micklefield J. Nat Prod Rep 2015, 33, 317-347.

Sequence CWU 1

1

136138DNAArtificial SequencePrimer According to Table 1 1catcaccatc atcaccaccc tcaacaacct gtcacggc 38246DNAArtificial SequencePrimer Sequence According to Table 1 2cagcctaggt taattaagct gttaagtcag atcaatcagc ggcaac 46321DNAArtificial SequencePrimer Sequence According to Table 1 3cagcttaatt aacctaggct g 21418DNAArtificial SequencePrimer Sequence According to Table 1 4gtggtgatga tggtgatg 18562DNAArtificial SequencePrimer Sequence According to Table 1 5tcatgaactc gccagaacca gcagcggagc cagcggatcc cagcgcctcc gcttcacaat 60tc 62620DNAArtificial SequencePrimer Sequence According to Table 1 6tggaatgcga ccgaagaacc 20760DNAArtificial SequencePrimer Sequence According to Table 1 7cacatacctg agtaggatac ggttcttcgg tcgcattcca agttttcagc aacaactggc 60860DNAArtificial SequencePrimer Sequence According to Table 1 8tgttttgcct gcatcggaac gcacgttgtt gctggaaacg tggaatacaa cggaaactgc 60917DNAArtificial SequencePrimer Sequence According to Table 1 9cgtttccagc aacaacg 171065DNAArtificial SequencePrimer Sequence According to Table 1 10ttctccatac ccgttttttt gggctaacag gaggaattcc atgaaagata gcatggctaa 60aaagg 651162DNAArtificial SequencePrimer Sequence According to Table 1 11tcatgaactc gccagaacca gcagcggagc cagcggatcc cagcgcctcc gcttcacaat 60tc 621220DNAArtificial SequencePrimer Sequence According to Table 1 12tggaatgcga ccgaagaacc 201319DNAArtificial SequencePrimer Sequence According to Table 1 13aagccattga cgctgccag 191460DNAArtificial SequencePrimer Sequence According to Table 1 14tgttttgcct gcatcggaac gcacgttgtt gctggaaacg tggaatacaa cggaaactgc 601517DNAArtificial SequencePrimer Sequence According to Table 1 15cgtttccagc aacaacg 171665DNAArtificial SequencePrimer Sequence According to Table 1 16ttctccatac ccgttttttt gggctaacag gaggaattcc atgaaagata gcatggctaa 60aaagg 651764DNAArtificial SequencePrimer Sequence According to Table 1 17cacatacctg agtaggatac ggttcttcgg tcgcattcca attttccagt aataactccc 60gctc 641860DNAArtificial SequencePrimer Sequence According to Table 1 18tcaatatcct gattatgcgg tctggcagcg tcaatggctt tcaggtgaag gagtacaggc 601970DNAArtificial SequencePrimer Sequence According to Table 1 19actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agatagcatg 60gctaaaaagg 702061DNAArtificial SequencePrimer Sequence According to Table 1 20cccaatcaac atatcggtaa aaaagcgagt atgttccatc tggctcaccc cctggtgggc 60c 612165DNAArtificial SequencePrimer Sequence According to Table 1 21cccgtacctt tccgtaatct ggtcgctcag gcccaccagg gggtgagcca gatggaacat 60actcg 652262DNAArtificial SequencePrimer Sequence According to Table 1 22cgtccgacgc caataatcac tctgtgcctg tactccttca cctgaaaacc actggcgttg 60cc 622322DNAArtificial SequencePrimer Sequence According to Table 1 23tcaggtgaag gagtacaggc ac 222416DNAArtificial SequencePrimer Sequence According to Table 1 24gacaccctgc cgagcc 162564DNAArtificial SequencePrimer Sequence According to Table 1 25ccggtcccgt tccgccattt agtggcacag gctcggcagg gtgtccaagg cgctgttctc 60actg 642662DNAArtificial SequencePrimer Sequence According to Table 1 26ctcagccaac atttcagtaa agaaacgggt atgttcagcc tgactcacgc tcagggtctg 60gg 622720DNAArtificial SequencePrimer Sequence According to Table 1 27agtcaggctg aacatacccg 202862DNAArtificial SequencePrimer Sequence According to Table 1 28tttgctcatg aactcgccag aaccagcagc ggagccagcg gatcccagcg cctccgcttc 60ac 622970DNAArtificial SequencePrimer Sequence According to Table 1 29actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agatagcatg 60gctaaaaagg 703061DNAArtificial SequencePrimer Sequence According to Table 1 30cccaatcaac atatcggtaa aaaagcgagt atgttccatc tggctcaccc cctggtgggc 60c 613165DNAArtificial SequencePrimer Sequence According to Table 1 31cccgtacctt tccgtaatct ggtcgctcag gcccaccagg gggtgagcca gatggaacat 60actcg 653262DNAArtificial SequencePrimer Sequence According to Table 1 32cgtccgacgc caataatcac tctgtgcctg tactccttca cctgaaaacc actggcgttg 60cc 623322DNAArtificial SequencePrimer Sequence According to Table 1 33tcaggtgaag gagtacaggc ac 223416DNAArtificial SequencePrimer Sequence According to Table 1 34gacaccctgc cgagcc 163564DNAArtificial SequencePrimer Sequence According to Table 1 35gccggtcccg ttccgccatt tagtggcaca ggctcggcag ggtgtcagtc aggaagccca 60cacc 643661DNAArtificial SequencePrimer Sequence According to Table 1 36ctcagccaac atttcagtaa agaaacgggt atgttcagcc tgactcaccc ccaaccgaac 60c 613720DNAArtificial SequencePrimer Sequence According to Table 1 37agtcaggctg aacatacccg 203862DNAArtificial SequencePrimer Sequence According to Table 1 38tttgctcatg aactcgccag aaccagcagc ggagccagcg gatcccagcg cctccgcttc 60ac 6239111DNAArtificial SequencePrimer Sequence According to Table 1 39agattagcgg atcctacctg acgcttttta tcgcaactct ctactgtttc tccatacccg 60tttttttggg ctaacaggag gaattccatg aaagataaca ttgctacagt g 1114021DNAArtificial SequencePrimer Sequence According to Table 1 40ccaataatca ctctgtgcct g 214120DNAArtificial SequencePrimer Sequence According to Table 1 41gaactggttg cactttacgc 204218DNAArtificial SequencePrimer Sequence According to Table 1 42catccctaac cgggactg 184398DNAArtificial SequencePrimer Sequence According to Table 1 43cataccttga cggacagggc ggcaacctgc cagcgccggc acccttccgc aatctggtag 60cgcagtcccg gttagggatg agtcaggcag cccatacc 9844103DNAArtificial SequencePrimer Sequence According to Table 1 44aacaacaccg gtaaacagtt cttcaccttt gctcatgaac tcgccagaac cagcagcgga 60gccagcggat ccggcgcgcc ctattgctct gctgatatca gaa 1034520DNAArtificial SequencePrimer Sequence According to Table 1 45gaccagacag aacatcaccg 204618DNAArtificial SequencePrimer Sequence According to Table 1 46ggcccaatcc tatacgcc 184719DNAArtificial SequencePrimer Sequence According to Table 1 47cttaccaagc gccacaagg 194896DNAArtificial SequencePrimer Sequence According to Table 1 48agaatcggaa caacaccggt aaacagttct tcacctttgc tcatgaactc gccagaacca 60gcagcggagc cagcggatcc cagcgcctcc gcttca 964996DNAArtificial SequencePrimer Sequence According to Table 1 49tcggtcagcc caaacggtaa tgtcggttca tccacttctg ccaacatgtc ggtaaagaat 60cggtgatgtt ctgtctggtc gacaccctgc cgagcc 965096DNAArtificial SequencePrimer Sequence According to Table 1 50atcctacctg acgcttttta tcgcaactct ctactgtttc tccatacccg tttttttggg 60ctaacaggag gaattccatg cgggcaatgg tgaacc 965120DNAArtificial SequencePrimer Sequence According to Table 1 51gaccagacag aacatcaccg 205218DNAArtificial SequencePrimer Sequence According to Table 1 52ggcccaatcc tatacgcc 185319DNAArtificial SequencePrimer Sequence According to Table 1 53cttaccaagc gccacaagg 195496DNAArtificial SequencePrimer Sequence According to Table 1 54agaatcggaa caacaccggt aaacagttct tcacctttgc tcatgaactc gccagaacca 60gcagcggagc cagcggatcc cagcgcctcc gcttca 965596DNAArtificial SequencePrimer Sequence According to Table 1 55tcggtcagcc caaacggtaa tgtcggttca tccacttctg ccaacatgtc ggtaaagaat 60cggtgatgtt ctgtctggtc gacaccctgc cgagcc 965696DNAArtificial SequencePrimer Sequence According to Table 1 56atcctacctg acgcttttta tcgcaactct ctactgtttc tccatacccg tttttttggg 60ctaacaggag gaattccatg tctgatgaag gcgtgc 965720DNAArtificial SequencePrimer Sequence According to Table 1 57gaccagacag aacatcaccg 205818DNAArtificial SequencePrimer Sequence According to Table 1 58ggcccaatcc tatacgcc 185919DNAArtificial SequencePrimer Sequence According to Table 1 59cttaccaagc gccacaagg 196096DNAArtificial SequencePrimer Sequence According to Table 1 60agaatcggaa caacaccggt aaacagttct tcacctttgc tcatgaactc gccagaacca 60gcagcggagc cagcggatcc cagcgcctcc gcttca 966196DNAArtificial SequencePrimer Sequence According to Table 1 61tcggtcagcc caaacggtaa tgtcggttca tccacttctg ccaacatgtc ggtaaagaat 60cggtgatgtt ctgtctggtc gacaccctgc cgagcc 9662102DNAArtificial SequencePrimer Sequence According to Table 1 62atcctacctg acgcttttta tcgcaactct ctactgtttc tccatacccg tttttttggg 60ctaacaggag gaattccatg gcatttaccg aaaagatctg cg 10263106DNAArtificial SequencePrimer Sequence According to Table 1 63cggatcctac ctgacgcttt ttatcgcaac tctctactgt ttctccatac ccgttttttt 60gggctaacag gaggaattcc atgaaagata gcatggctaa aaaggg 1066499DNAArtificial SequencePrimer Sequence According to Table 1 64ctatcggcaa ttcaagtaac accggtgcat ctgccaacgt ccgacgccaa taatcactct 60gtgcctgtac tccttcacct gaaaatacct gccgctgcc 9965104DNAArtificial SequencePrimer Sequence According to Table 1 65gcttgtctga atcaacaacc tgatccgctg ccgccattga ccattcaata tcctgattat 60gctgcctggc agcggcaggt attttcaggt gaaggagtac aggc 10466101DNAArtificial SequencePrimer Sequence According to Table 1 66gcacttccga caatccaaat gacaacgttg gctcatctac ctcagccaac atatcggtaa 60agaaacgggt atgttctgcc tgactgacac cctgccgagc c 10167102DNAArtificial SequencePrimer Sequence According to Table 1 67ggcttgcctc ttggggcaaa tggatagcct gcctgcgccg gtcccgttcc gccatttagt 60ggcacaggct cggcagggtg tcagtcaggc agaacatacc cg 1026898DNAArtificial SequencePrimer Sequence According to Table 1 68ccagaatcgg aacaacaccg gtaaacagtt cttcaccttt gctcatgaac tcgccagaac 60cagcagcgga gccagcggat cccagcgcct ccacttcg 986966DNAArtificial SequencePrimer Sequence According to Table 1 69accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcggt tgaacgctta 60caatcc 667063DNAArtificial SequencePrimer Sequence According to Table 1 70ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactgatac ccagccgggc 60ttg 637167DNAArtificial SequencePrimer Sequence According to Table 1 71accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcatc ggaacgggta 60caaattc 677263DNAArtificial SequencePrimer Sequence According to Table 1 72ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgacttaccc ccatccgtgc 60ctg 637367DNAArtificial SequencePrimer Sequence According to Table 1 73accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcggc agcacagata 60cagtctc 677461DNAArtificial SequencePrimer Sequence According to Table 1 74ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactcacgc ccaaccggac 60c 617569DNAArtificial SequencePrimer Sequence According to Table 1 75accattcaat atcctgatta tgcggcttgg cagcggcagg tattttctgc tgatcgtatt 60caggtgcag 697661DNAArtificial SequencePrimer Sequence According to Table 1 76ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactcacgc ccaaccggac 60c 617797DNAArtificial SequencePrimer Sequence According to Table 1 77gtctaaatca acagccagat ccgttgttgc cattgaccat tcaatatcct gattatgcgg 60cttggcagcg gcaggtattt cagggtgacc gcctgac 9778105DNAArtificial SequencePrimer Sequence According to Table 1 78tccgccaacc caaatagcag cgtcggttca tccacctcag ccaacatgtc agtaaagaag 60cgagtatgtt ctgcctgact cacactcagg atttgagcga taaag 1057967DNAArtificial SequencePrimer Sequence According to Table 1 79accattcaat atcctgatta tgcggcttgg cagcggcagg tatttcaggg tgaggtactg 60gaaaagc 678063DNAArtificial SequencePrimer Sequence According to Table 1 80ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgacttacac tgcgggtttg 60ggc 638170DNAArtificial SequencePrimer Sequence According to Table 1 81actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agatagcatg 60gctaaaaagg 708217DNAArtificial SequencePrimer Sequence According to Table 1 82aaatacctgc cgctgcc 178329DNAArtificial SequencePrimer Sequence According to Table 1 83agtcaggcag aacatactcg cttctttac 298462DNAArtificial SequencePrimer Sequence According to Table 1 84tttgctcatg aactcgccag aaccagcagc ggagccagcg gatcccagcg cctccgcttc 60ac 628563DNAArtificial SequencePrimer Sequence According to Table 1 85ttctgccaac atgtcggtaa agaatcggtg atgttctgtc tggtcttccc ccaaccagga 60ctg 638669DNAArtificial SequencePrimer Sequence According to Table 1 86actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agataacatg 60gctacaacg 698763DNAArtificial SequencePrimer Sequence According to Table 1 87ttctgccaac atgtcggtaa agaatcggtg atgttctgtc tggtccatcc ccaaccagga 60ctg 638870DNAArtificial SequencePrimer Sequence According to Table 1 88actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agataacatt 60gctacagtgg 708966DNAArtificial SequencePrimer Sequence According to Table 1 89ttctgccaac atgtcggtaa agaatcggtg atgttctgtc tggtcaacgc ccagccgggc 60ttgagc 669073DNAArtificial SequencePrimer Sequence According to Table 1 90actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa aaatgataag 60gtgatgactc tgc 739161DNAArtificial SequencePrimer Sequence According to Table 1 91ttctgccaac atgtcggtaa agaatcggtg atgttctgtc tggtccaccc cctggtgggc 60c 619270DNAArtificial SequencePrimer Sequence According to Table 1 92actgtttctc catacccgtt tttttgggct aacaggagga attccatgaa agatagcatg 60gctaaaaagg 709362DNAArtificial SequencePrimer Sequence According to Table 1 93accattcaat atcctgatta tgcggcttgg cagcggcagg tatttcaggg tgaccgcctg 60ac 629470DNAArtificial SequencePrimer Sequence According to Table 1 94ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactcacac tcaggatttg 60agcgataaag 709566DNAArtificial SequencePrimer Sequence According to Table 1 95accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcggt tgaacgctta

60caatcc 669663DNAArtificial SequencePrimer Sequence According to Table 1 96ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactgatac ccagccgggc 60ttg 639767DNAArtificial SequencePrimer Sequence According to Table 1 97accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcatc ggaacgggta 60caaattc 679863DNAArtificial SequencePrimer Sequence According to Table 1 98ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgacttaccc ccatccgtgc 60ctg 639967DNAArtificial SequencePrimer Sequence According to Table 1 99accattcaat atcctgatta tgcggcttgg cagcggcagg tattttcggc agcacagata 60cagtctc 6710061DNAArtificial SequencePrimer Sequence According to Table 1 100ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactcacgc ccaaccggac 60c 6110169DNAArtificial SequencePrimer Sequence According to Table 1 101accattcaat atcctgatta tgcggcttgg cagcggcagg tattttctgc tgatcgtatt 60caggtgcag 6910261DNAArtificial SequencePrimer Sequence According to Table 1 102ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgactcacgc ccaaccggac 60c 6110367DNAArtificial SequencePrimer Sequence According to Table 1 103accattcaat atcctgatta tgcggcttgg cagcggcagg tatttcaggg tgaggtactg 60gaaaagc 6710463DNAArtificial SequencePrimer Sequence According to Table 1 104ctcagccaac atgtcagtaa agaagcgagt atgttctgcc tgacttacac tgcgggtttg 60ggc 6310529DNAArtificial SequencePrimer Sequence According to Table 1 105agtcaggcag aacatactcg cttctttac 2910662DNAArtificial SequencePrimer Sequence According to Table 1 106tttgctcatg aactcgccag aaccagcagc ggagccagcg gatcccagcg cctccgcttc 60ac 6210720DNAArtificial SequencePrimer Sequence According to Table 1 107gaccagacag aacatcaccg 2010817DNAArtificial SequencePrimer Sequence According to Table 1 108aaatacctgc cgctgcc 1710959DNAArtificial SequencePrimer Sequence According to Table 1 109ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact cacactcagg atttgagcg 5911060DNAArtificial SequencePrimer Sequence According to Table 1 110attcaatatc ctgattatgc ggcttggcag cggcaggtat ttcagggtga ccgcctgacc 6011161DNAArtificial SequencePrimer Sequence According to Table 1 111ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact catacctaga cgtgcctgtg 60c 6111264DNAArtificial SequencePrimer Sequence According to Table 1 112attcaatatc ctgattatgc ggcttggcag cggcaggtat tttcggcaga acggatacaa 60attc 6411356DNAArtificial SequencePrimer Sequence According to Table 1 113ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact cacgcccaac cggacc 5611462DNAArtificial SequencePrimer Sequence According to Table 1 114attcaatatc ctgattatgc ggcttggcag cggcaggtat tttcggcagc acagatacag 60tc 6211560DNAArtificial SequencePrimer Sequence According to Table 1 115aaatacctgc cgctgccaag ccgcataatc aggatattga atcgtcaacg gtagcaacgg 6011660DNAArtificial SequencePrimer Sequence According to Table 1 116acctttccgc aatctggtgg ctcaggctcg gcagggggtt agtcaggctg agcatacccg 6011756DNAArtificial SequencePrimer Sequence According to Table 1 117ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact cacgcccaac cggacc 5611864DNAArtificial SequencePrimer Sequence According to Table 1 118attcaatatc ctgattatgc ggcttggcag cggcaggtat tttctgctga tcgtattcag 60gtgc 6411962DNAArtificial SequencePrimer Sequence According to Table 1 119tcatgaactc gccagaacca gcagcggagc cagcggatcc cagcgcctcc gcttcacaat 60tc 6212021DNAArtificial SequencePrimer Sequence According to Table 1 120agtcaggcag aacatactcg c 2112116DNAArtificial SequencePrimer Sequence According to Table 1 121aaccccctgc cgagcc 1612216DNAArtificial SequencePrimer Sequence According to Table 1 122aaccccctgc cgagcc 1612360DNAArtificial SequencePrimer Sequence According to Table 1 123aaatacctgc cgctgccaag ccgcataatc aggatattga attgccaatg gtggcaaggg 6012460DNAArtificial SequencePrimer Sequence According to Table 1 124acctttccgc aatctggtgg ctcaggctcg gcagggggtt agccagacag agcacacccg 6012561DNAArtificial SequencePrimer Sequence According to Table 1 125ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact gatacccagc cgggcttgtg 60c 6112663DNAArtificial SequencePrimer Sequence According to Table 1 126attcaatatc ctgattatgc ggcttggcag cggcaggtat tttcggttga acgcttacaa 60tcc 6312756DNAArtificial SequencePrimer Sequence According to Table 1 127ccaacatgtc agtaaagaag cgagtatgtt ctgcctgact gacaccctgc cgagcc 5612861DNAArtificial SequencePrimer Sequence According to Table 1 128attcaatatc ctgattatgc ggcttggcag cggcaggtat tttctgatga aggcgtgcag 60g 6112960DNAArtificial SequencePrimer Sequence According to Table 1 129aaatacctgc cgctgccaag ccgcataatc aggatattga atggtcaatg gcggcagcgg 6013060DNAArtificial SequencePrimer Sequence According to Table 1 130acctttccgc aatctggtgg ctcaggctcg gcagggggtt agtcaggaag cgtacacgcg 601317PRTUnknownSequence motif in C domains in multiple organismsmisc_feature(3)..(5)Xaa can be any naturally occurring amino acid 131His His Xaa Xaa Xaa Asp Gly1 51325PRTUnknownConserved sequence in the C-A linker 132Trp Asn Ala Thr Glu1 513332PRTArtificial SequenceConsensus sequence according to Figure 1 133Ile Gln Tyr Ala Asp Tyr Ala Val Trp Gln Arg Gln Trp Leu Gln Gly1 5 10 15Glu Arg Leu Thr Glu Gln Arg Asp Phe Trp Arg Thr Gln Leu Ala Gly 20 25 3013439DNAArtificial SequenceConsensus sequence according to Figure 7 134caacatgtca gtaaagaagc gagtatgttc tgcctgact 3913513PRTArtificial SequenceTranslation of consensus sequences according to Figure 7 135Leu Met Asp Thr Phe Phe Arg Thr His Glu Ala Gln Ser1 5 1013639DNAArtificial SequenceComplement sequence according to Figure 7 136gttgtacagt catttcttcg ctcatacaag acggactga 39

Claims

1. A system for the production of a non-ribosomal peptide synthases (NRPS), wherein the system comprises at least one, preferably two, NRPS eXchange Units (XU.sub.2.0) each specific for a different or identical amino acid X for assembling an NRPS, and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (C.sub.Asub) specific for a given amino acid X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) specific for a given amino acid X, a condensation-domain donor site subdomain (C.sub.Dsub) specific for a given amino acid X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) specific for a given amino acid X.

2. The system according to claim 1, wherein at least one XU.sub.2.0 comprises a C- or C/E acceptor domain and a C- or C/E donor domain separated by one or more NRPS domains other than C or C/E domains.

3. The system according to claim 1 or 2, wherein at least a first and a second XU.sub.2.0 of the system, when connected to each other, form a functional assembled C or C/E domain composed of one partial C or C/E domain of the first XU.sub.2.0 and one partial C or C/E domain of the second XU.sub.2.0.

4. The system according to any one of claims 1 to 3, comprising at least two XU.sub.2.0 of which each has a different amino acid specificity X, preferably wherein each X is selected from a specificity to any one or two, three, four or more natural or non-natural amino acid.

5. The system according to any one of claims 1 to 7, the system further comprising a XU.sub.2.0 termination and/or initiation unit, wherein the XU.sub.2.0 initiation unit comprises only a C or C/E domain donor subdomain, a domain structure C-A.sup.X-T-C.sub.Dsub.sup.X or C-A.sup.X-T-C/E.sub.Dsub.sup.X, specific for the incorporation of acyl units (fatty acids and their derivatives) as starting units, and wherein the termination module comprises any one of a terminal condensation domain (Cterm), an internal condensation (C) domain, an internal condensation and epimerization (C/E)-didomain, a cyclization (Cy) domain, an epimerization (E) domain, a reduction (R), an oxidation (Ox) or a thioesterase (TE) domain.

6. The system according to any one of claims 1 to 7, the system further comprising a XU2.0 initiation unit, preferably selected from the formulas: C.sub.Asub-A.sup.X-T-C.sub.Dsub.sup.X, C/E.sub.Asub-A.sup.X-C.sub.Dsub.sup.X, C.sub.Asub-A.sup.X-T-E/E.sub.Dsub.sup.X, or C/E.sub.Asub-A.sup.X-T-C/E.sub.Dsub.sup.X

7. The system according to any one of claims 1 to 9, wherein at least two, preferably three, four, or more, XU.sub.2.0 when put into sequence provide the NRPS.

8. The system according to any one of claims 1 to 7, further comprising at least one XU.sub.2.0 having a modification domain, such as an E, MT or Ox or other modification domain.

9. An isolated nucleic acid, comprising a partial non-ribosomal peptide synthases (NRPS) condensation (C)-domain sequence or partial NRPS condensation/epimerization (C/E)-domain sequence, wherein said sequence encodes for at least a partial C or C/E domain comprising a C or C/E domain donor or acceptor site, but does not encode for a partial or full-length C or C/E domain comprising a functionally connected donor and acceptor site.

10. A library of nucleic acid molecules, wherein the library comprises at least two or more nucleic acid constructs each encoding a NRPS eXchange Unit (XU2.0) having an amino acid specificity X, and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (C.sub.Asub) having an amino acid specificity X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) having an amino acid specificity X, a condensation-domain donor site sub-domain (C.sub.Dsub) having an amino acid specificity X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) having an amino acid specificity X.

11. The library according to claim 10, comprising nucleic acid constructs encoding at least one XU.sub.2.0 termination and/or initiation unit, wherein the XU.sub.2.0 initiation unit comprises only a C or C/E domain donor subdomain, a domain structure C-A.sup.X-T-C.sub.Dsub.sup.X or C-A.sup.X-T-C/E.sub.Dsub.sup.X, specific for the incorporation of acyl units (fatty acids and their derivatives) as starting units, or A.sup.X-T-C.sub.Dsub.sup.X or A.sup.X-T-C/E.sub.DSub.sup.X, and wherein the termination module comprises any one of a terminal condensation domain (Cterm), an internal condensation (C) domain, an internal condensation and epimerization (C/E)-didomain, a cyclization (Cy) domain, an epimerization (E) domain, a reduction (R), an oxidation (Ox) or a thioesterase (TE) domain

12. The library according to claim 10 or 11, wherein each XU.sub.2.0 is encoded by a separate nucleic acid construct, preferably by a nucleic acid according to claim 9.

13. The library according to any one of claims 10 to 12, wherein the library comprises the XU.sub.2.0 of the system according to any one of claims 1 to 8.

14. A method for producing a NRPS, the method comprising a step of assembling at least two NRPS eXchange Units (XU.sub.2.0) each having an identical or different amino acid specificity X, and wherein the XU.sub.2.0 comprises at least one partial condensation (C)- or partial condensation/epimerization (C/E)-domain selected from the group consisting of a condensation-domain acceptor site subdomain (CAsub) having an amino acid specificity X, a condensation/epimerization-domain acceptor site subdomain (C/E.sub.Asub) having an amino acid specificity X, a condensation-domain donor site subdomain (C.sub.Dsub) having an amino acid specificity X and a condensation/epimerization-domain donor site subdomain (C/E.sub.Dsub) having an amino acid specificity X.

15. A method for the production of non-ribosomal peptides having a specific sequence, the method comprising assembling a NRPS according to the method of claim 14, wherein the NRPS is composed of a sequence of XU.sub.2.0 having specificity according to the non-ribosomal peptide to be produced.